

10/529,895

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal600txm

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

only hits with sugars are

10, 11, & 12

12 is my app.

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 JAN 02 STN pricing information for 2008 now available  
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified  
prophetic substances  
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new  
custom IPC display formats  
NEWS 5 JAN 28 MARPAT searching enhanced  
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days  
of publication  
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment  
NEWS 8 JAN 28 MEDLINE and LMEEDLINE reloaded with enhancements  
NEWS 9 FEB 08 STN Express, Version 8.3, now available  
NEWS 10 FEB 20 PCI now available as a replacement to DPCI  
NEWS 11 FEB 25 IFIREF reloaded with enhancements  
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements  
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current  
U.S. National Patent Classification  
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom  
IPC display formats  
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental  
spectra  
NEWS 16 MAR 31 CA/CAPLUS and CASREACT patent number format for U.S.  
applications updated  
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI  
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements  
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued  
NEWS 20 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new  
predefined hit display formats  
NEWS 21 APR 28 EMBASE Controlled Term thesaurus enhanced  
NEWS 22 APR 28 IMSRESEARCH reloaded with enhancements  
NEWS 23 MAY 30 INPAPAMDB now available on STN for patent family  
searching  
NEWS 24 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology  
sequence search option  
NEWS 25 JUN 06 EPFULL enhanced with 260,000 English abstracts  
NEWS 26 JUN 06 KOREAPAT updated with 41,000 documents  
NEWS 27 JUN 13 USPATFULL and USPAT2 updated with 11-character  
patent numbers for U.S. applications  
NEWS 28 JUN 19 CAS REGISTRY includes selected substances from  
web-based collections  
  
NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

McIntosh

10/529,895

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:24:11 ON 19 JUN 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:24:29 ON 19 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 JUN 2008 HIGHEST RN 1029146-45-9

DICTIONARY FILE UPDATES: 18 JUN 2008 HIGHEST RN 1029146-45-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10529895.str

L1 STRUCTURE UPLOADED

=> s l1

SAMPLE SEARCH INITIATED 17:24:46 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 30610 TO ITERATE

6.5% PROCESSED 2000 ITERATIONS 0 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 601736 TO 622664  
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> d l1

L1 HAS NO ANSWERS

L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 17:24:53 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 614862 TO ITERATE

100.0% PROCESSED 614862 ITERATIONS 307 ANSWERS  
SEARCH TIME: 00.00.09

L3 307 SEA SSS FUL L1

=> file caplus

McIntosh

10/529,895

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	178.36	178.57

FILE 'CAPLUS' ENTERED AT 17:25:08 ON 19 JUN 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Jun 2008 VOL 148 ISS 25  
FILE LAST UPDATED: 18 Jun 2008 (20080618/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l3

L4 30 L3

=> d bib abs hitstr 1-30 l4

L4 ANSWER 1 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2008:419768 CAPLUS

DN 148:426885

TI Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists and their preparation, pharmaceutical compositions and use in the treatment of obesity and obesity-related metabolic disorders

IN Lee, Jinhwa; Kim, Jeong Min; Chang, Chong-Hwan Jonathan; Lee, Suk Ho; Seo, Hee Jeong; Kang, Suk Youn; Song, Kwang-Seop; Kim, Jong Yup; Kim, Min-Ah; Lee, Sung-Han; Ahn, Kwang-Woo; Jung, Myung Eun; Park, Ji-Hyun

PA Green Cross Corporation, S. Korea

SO PCT Int. Appl., 281pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008039023	A1	20080403	WO 2007-KR4754	20070928
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	US 20080081815	A1	20080403	US 2006-541269	20060929
PRAI	US 2006-541269	A	20060929		
	KR 2006-132606	A	20061222		
OS	MARPAT 148:426885				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

McIntosh

AB A heteroaryl-pyrazole compound of formula I or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The invention also provides a method for preparing the inventive heteroaryl-pyrazole compds. or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders. Compds. of formula I wherein R1 is H, (un)substituted C1-5 alkyl, (un)substituted C2-4 alkenyl, (un)substituted C2-4 alkynyl, halo, etc.; R2 is H, NH2 and derivs., (un)substituted carbocycle, (un)substituted (hetero)aryl, (un)substituted heterocycle, etc.; R6, R7, R8, R9, R10, and R11 are independently H, halo, C1-3 alkyl, C1-3 alkoxy and CF3; X Y and Z are independently, =CR12, O, N=, NH and derivs., and S to form an aromatic heterocycle with Q and T; Q and T are independently C=, and N, with the proviso that both Q and T are not N at the same time; R12 are H, NH2 and derivative, (un)substituted carbocycle, (un)substituted (hetero)aryl, etc.; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by hydrazination of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with butanoic acid hydrazide; the resulting N-butanoyl-N'-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carbonyl]hydrazine underwent microwave-mediated cyclization to give compound II. All the invention compds. were evaluated for their CB1 antagonistic activity (some data given).


IT 1016553-07-3P 1016553-08-4P 1016553-09-5P  
 1016553-12-0P 1016553-13-1P 1016553-14-2P  
 1016553-15-3P 1016553-16-4P 1016553-17-5P  
 1016553-18-6P 1016553-19-7P 1016553-20-0P  
 1016553-21-1P 1016553-22-2P 1016553-27-7P  
 1016553-28-8P 1016553-29-9P 1016553-30-2P  
 1016553-31-3P 1016553-33-5P 1016553-34-6P  
 1016553-35-7P 1016553-36-8P 1016553-37-9P  
 1016553-38-0P 1016553-39-1P 1016553-40-4P  
 1016553-41-5P 1016553-42-6P 1016553-43-7P  
 1016553-44-8P 1016553-45-9P 1016553-46-0P  
 1016553-47-1P 1016555-30-8P 1016555-32-0P  
 1016555-34-2P 1016555-36-4P 1016555-37-5P  
 1016555-39-7P 1016555-41-1P 1016555-43-3P  
 1016555-44-4P 1016555-45-5P 1016555-47-7P  
 1016555-49-9P 1016555-51-3P 1016555-52-4P  
 1016555-53-5P 1016555-55-7P 1016555-56-8P  
 1016555-58-0P 1016557-46-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of heteroaryl-pyrazole derivs. as cannabinoid CB1 receptor antagonists useful in the treatment of obesity and obesity-related metabolic disorders)

RN 1016553-07-3 CAPLUS


CN Piperidine, 1-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




RN 1016553-08-4 CAPLUS

CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1-pyrrolidinylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)


10/529,895



RN 1016553-09-5 CAPLUS  
CN Morpholine, 4-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




RN 1016553-12-0 CAPLUS  
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 1016553-13-1 CAPLUS  
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-imidazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)

McIntosh


10/529,895



RN 1016553-14-2 CAPLUS  
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-pyrazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 1016553-15-3 CAPLUS  
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-pyrazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 1016553-16-4 CAPLUS  
CN 1H-Tetrazole, 1-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-ylmethyl]-1H-pyrazol-1-ylmethyl]-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)

McIntosh


10/529,895



RN 1016553-17-5 CAPLUS  
CN 2H-Tetrazole, 2-[[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




RN 1016553-18-6 CAPLUS  
CN 1H-Tetrazole, 1-[[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




RN 1016553-19-7 CAPLUS  
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,3-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)

10/529,895




RN 1016553-20-0 CAPLUS

CN 2,5-Pyrrolidinedione, 1-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1016553-21-1 CAPLUS


CN 2-Pyrrolidinone, 1-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1016553-22-2 CAPLUS


CN 2-Oxazolidinone, 3-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)

McIntosh




RN 1016553-27-7 CAPLUS

CN 1,3,4-Oxadiazole, 2-[1-(4-chlorophenyl)cyclopropyl]-5-[5-(4-chlorophenyl)-  
1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-  
(CA INDEX NAME)



RN 1016553-28-8 CAPLUS

CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclopropyl]-  
(CA INDEX NAME)




RN 1016553-29-9 CAPLUS


CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-cyclobutyl- (CA INDEX NAME)

McIntosh

PAGE 1-A




PAGE 2-A




RN 1016553-30-2 CAPLUS

CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-cyclohexyl- (CA INDEX NAME)



RN 1016553-31-3 CAPLUS


CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-phenylcyclopropyl)- (CA INDEX NAME)



RN 1016553-33-5 CAPLUS


CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(4-methylphenyl)cyclopropyl]- (CA INDEX NAME)

10/529,895




RN 1016553-34-6 CAPLUS

CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(4-methoxyphenyl)cyclopropyl]-  
(CA INDEX NAME)



RN 1016553-35-7 CAPLUS

CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(2,4-dichlorophenyl)cyclopropyl]-  
(CA INDEX NAME)




RN 1016553-36-8 CAPLUS


CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclobutyl]-  
(CA INDEX NAME)

McIntosh

PAGE 1-A




PAGE 2-A




RN 1016553-37-9 CAPLUS  
 CN 1,3,4-Oxadiazole, 2-[1-(4-chlorophenyl)cyclobutyl]-5-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-  
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1016553-38-0 CAPLUS  
 CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-phenylcyclopentyl)-  
 (CA INDEX NAME)


10/529,895



RN 1016553-39-1 CAPLUS  
CN 1,3,4-Oxadiazole, 2-[1-(4-chlorophenyl)cyclopentyl]-5-[5-(4-chlorophenyl)-  
1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-  
(CA INDEX NAME)




RN 1016553-40-4 CAPLUS  
CN 1,3,4-Oxadiazole, 2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-(1H-1,2,4-  
triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX  
NAME)




RN 1016553-41-5 CAPLUS  
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-  
triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-methylcyclopropyl)- (CA INDEX  
NAME)

10/529,895




RN 1016553-42-6 CAPLUS

CN 1,3,4-Oxadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclopropyl]- (CA INDEX NAME)




RN 1016553-43-7 CAPLUS

CN 1,3,4-Oxadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(4-chlorophenyl)cyclopropyl]- (CA INDEX NAME)



RN 1016553-44-8 CAPLUS

CN 1,3,4-Oxadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)


CCCC1=NC(=O)N=C1C2=CN(C(=C2)C3=CC=C(C=C3)C4=CC(=CC=C4)Br)N(C5=CC(=CC=C5)Cl)C6=CC(=CC=C6)ClCCCC1=NC=NC(=O)C1C2=CN=C(N2)C3=CC=C(C=C3)Cl

Chemical structure of compound 10: 1-methyl-2-((4-chlorophenyl)methyl)-5-(4-chlorophenyl)-4-(4-chlorophenyl)-1H-1,2,4-triazole-3-carboxamide (tert-butyl). The structure features a central 1,2,4-triazole ring substituted with a tert-butyl group, a (4-chlorophenyl)methyl group, and a 4-chlorophenyl group.

McIntosh


10/529,895

CN 1H-Tetrazole, 5-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]-1-methyl-  
(CA INDEX NAME)




RN 1016555-30-8 CAPLUS

CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA  
INDEX NAME)



RN 1016555-32-0 CAPLUS

CN 1,3,4-Thiadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX  
NAME)




RN 1016555-34-2 CAPLUS


CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-cyclobutyl- (CA INDEX NAME)

McIntosh

PAGE 1-A




PAGE 2-A




RN 1016555-36-4 CAPLUS

CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-cyclohexyl- (CA INDEX NAME)



RN 1016555-37-5 CAPLUS


CN 1,3,4-Thiadiazole, 2-[1-(4-chlorophenyl)cyclopropyl]-5-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1016555-39-7 CAPLUS

CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-phenylcyclopropyl)- (CA INDEX NAME)


10/529,895



RN 1016555-41-1 CAPLUS  
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(4-methylphenyl)cyclopropyl]- (CA INDEX NAME)




RN 1016555-43-3 CAPLUS  
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(4-methoxyphenyl)cyclopropyl]- (CA INDEX NAME)




RN 1016555-44-4 CAPLUS  
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(2,4-dichlorophenyl)cyclopropyl]- (CA INDEX NAME)

McIntosh

10/529,895




RN 1016555-45-5 CAPLUS  
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclopropyl]- (CA INDEX NAME)




RN 1016555-47-7 CAPLUS  
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclobutyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 1016555-49-9 CAPLUS  
CN 1,3,4-Thiadiazole, 2-[1-(4-chlorophenyl)cyclobutyl]-5-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)

McIntosh


10/529,895

(CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1016555-51-3 CAPLUS  
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-phenylcyclopentyl)- (CA INDEX NAME)




RN 1016555-52-4 CAPLUS  
CN 1,3,4-Thiadiazole, 2-[1-(4-chlorophenyl)cyclopentyl]-5-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)


10/529,895



RN 1016555-53-5 CAPLUS  
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-methylcyclopropyl)- (CA INDEX NAME)




RN 1016555-55-7 CAPLUS  
CN 1,3,4-Thiadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclopropyl]- (CA INDEX NAME)



RN 1016555-56-8 CAPLUS  
CN 1,3,4-Thiadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(4-chlorophenyl)cyclopropyl]- (CA INDEX NAME)


McIntosh

10/529,895




RN 1016555-58-0 CAPLUS

CN 1,3,4-Thiadiazole, 2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1016557-46-2 CAPLUS

CN 1,3,4-Oxadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-methylcyclopropyl)- (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2008:416137 CAPLUS

DN 148:426884

TI Heteroaryl-pyrazole derivatives as cannabinoid CB1 receptor antagonists and their preparation, pharmaceutical compositions and use in the treatment of obesity and obesity-related metabolic disorders

IN Lee, Jinhwa; Kim, Jeong Min; Chang, Chong-Hwan Jonathan; Lee, Suk Ho; Seo, Hee Jeong; Kang, Suk Youn; Song, Kwang-Seop; Kim, Jong Yup; Kim, Min-Ah; Lee, Sung-Han; Ahn, Kwang-Woo; Jung, Myung Eun; Park, Ji-Hyun

PA Green Cross Corporation, S. Korea

SO U.S. Pat. Appl. Publ., 124pp., Cont.-in-part of U. S. Ser. No. 541,269.  
CODEN: USXXCO

DT Patent

McIntosh

10/529,895

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----		-----	-----	-----
PI	US 20080081812	A1	20080403	US 2007-863501	20070928
	US 20080081815	A1	20080403	US 2006-541269	20060929
PRAI	US 2006-541269	A2	20060929		
OS	MARPAT 148:426884				
GI					

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB A heteroaryl-pyrazole compound of formula I or a pharmaceutically acceptable salt thereof is effective as a cannabinoid CB1 receptor inverse agonist or antagonist, which is useful for preventing or treating obesity and obesity-related metabolic disorders. The invention also provides a method for preparing the inventive heteroaryl-pyrazole compds. or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating obesity and obesity-related metabolic disorders. Compds. of formula I wherein R1 is H, (un)substituted C1-5 alkyl, (un)substituted C2-4 alkenyl, (un)substituted C2-4 alkynyl, halo, etc.; R2 is H, NH2 and derivs., (un)substituted carbocycle, (un)substituted (hetero)aryl, (un)substituted heterocycle, etc.; R6, R7, R8, R9, R10, and R11 are independently H, halo, C1-3 alkyl, C1-3 alkoxy and CF3; X Y and Z are independently, =CR12, O, N=, NH and derivs., and S to form an aromatic heterocycle with Q and T; Q and T are independently C=, and N, with the proviso that both Q and T are not N at the same time; R12 are H, NH2 and derivative, (un)substituted carbocycle, (un)substituted (hetero)aryl, etc.; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by hydrazination of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxylic acid with butanoic acid hydrazide; the resulting N-butanoyl-N'-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carbonyl]hydrazine underwent microwave-mediated cyclization to give compound II. All the invention compds. were evaluated for their CB1 antagonistic activity (some data given).

IT 1016553-07-3P 1016553-08-4P 1016553-09-5P  
1016553-12-0P 1016553-13-1P 1016553-14-2P  
1016553-15-3P 1016553-16-4P 1016553-17-5P  
1016553-18-6P 1016553-19-7P 1016553-20-0P  
1016553-21-1P 1016553-22-2P 1016553-27-7P  
1016553-28-8P 1016553-29-9P 1016553-30-2P  
1016553-31-3P 1016553-33-5P 1016553-34-6P  
1016553-35-7P 1016553-36-8P 1016553-37-9P  
1016553-38-0P 1016553-39-1P 1016553-40-4P  
1016553-41-5P 1016553-42-6P 1016553-43-7P  
1016553-44-8P 1016553-45-9P 1016553-46-0P  
1016553-47-1P 1016555-30-8P 1016555-32-0P  
1016555-34-2P 1016555-36-4P 1016555-37-5P  
1016555-39-7P 1016555-41-1P 1016555-43-3P  
1016555-44-4P 1016555-45-5P 1016555-47-7P  
1016555-49-9P 1016555-51-3P 1016555-52-4P  
1016555-53-5P 1016555-55-7P 1016555-56-8P  
1016555-58-0P 1016557-46-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of heteroaryl-pyrazole derivs. as cannabinoid CB1 receptor antagonists useful in the treatment of obesity and obesity-related metabolic disorders)

RN 1016553-07-3 CAPLUS


CN Piperidine, 1-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)

10/529,895




RN 1016553-08-4 CAPLUS

CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1-pyrrolidinylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1016553-09-5 CAPLUS

CN Morpholine, 4-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




RN 1016553-12-0 CAPLUS


CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)

McIntosh


10/529,895



RN 1016553-13-1 CAPLUS  
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-imidazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 1016553-14-2 CAPLUS  
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-pyrazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 1016553-15-3 CAPLUS  
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-pyrrol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)

10/529,895




RN 1016553-16-4 CAPLUS

CN 1H-Tetrazole, 1-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1016553-17-5 CAPLUS


CN 2H-Tetrazole, 2-[[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




RN 1016553-18-6 CAPLUS

CN 1H-Tetrazole, 1-[[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)


10/529,895



RN 1016553-19-7 CAPLUS  
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,3-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 1016553-20-0 CAPLUS  
CN 2,5-Pyrrolidinedione, 1-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1016553-21-1 CAPLUS  
CN 2-Pyrrolidinone, 1-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)


McIntosh

10/529,895




RN 1016553-22-2 CAPLUS

CN 2-Oxazolidinone, 3-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 1016553-27-7 CAPLUS

CN 1,3,4-Oxadiazole, 2-[1-(4-chlorophenyl)cyclopropyl]-5-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1016553-28-8 CAPLUS

CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclopropyl]- (CA INDEX NAME)

McIntosh


10/529,895




RN 1016553-29-9 CAPLUS

CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-cyclobutyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1016553-30-2 CAPLUS

CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-cyclohexyl- (CA INDEX NAME)



RN 1016553-31-3 CAPLUS

CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-phenylcyclopropyl)- (CA INDEX NAME)


McIntosh

CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(4-methylphenyl)cyclopropyl]-  
(CA INDEX NAME)

CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(4-methoxyphenyl)cyclopropyl]-  
(CA INDEX NAME)

CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(2,4-dichlorophenyl)cyclopropyl]-  
(CA INDEX NAME)


10/529,895




RN 1016553-36-8 CAPLUS

CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclobutyl]-  
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1016553-37-9 CAPLUS


CN 1,3,4-Oxadiazole, 2-[1-(4-chlorophenyl)cyclobutyl]-5-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-  
(CA INDEX NAME)

PAGE 1-A







RN 1016553-38-0 CAPLUS  
CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-phenylcyclopentyl)- (CA INDEX NAME)



RN 1016553-39-1 CAPLUS  
CN 1,3,4-Oxadiazole, 2-[1-(4-chlorophenyl)cyclopentyl]-5-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1016553-40-4 CAPLUS  
CN 1,3,4-Oxadiazole, 2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



10/529,895


RN 1016553-41-5 CAPLUS

CN 1,3,4-Oxadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-methylcyclopropyl)- (CA INDEX NAME)




RN 1016553-42-6 CAPLUS

CN 1,3,4-Oxadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclopropyl]- (CA INDEX NAME)



RN 1016553-43-7 CAPLUS


CN 1,3,4-Oxadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(4-chlorophenyl)cyclopropyl]- (CA INDEX NAME)



RN 1016553-44-8 CAPLUS

CN 1,3,4-Oxadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)


McIntosh

CCCC1=NC=CC(=O)N1C2=CN=C(N2C3=CC=CC=C3Br)N4=CC=C(Cl)C(Cl)=C4CC1=NC(=O)N=C1C2=CN(C(=N2)C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl

McIntosh


10/529,895

CN 1H-Tetrazole, 5-[[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-[5-(1,1-dimethylethyl)-1,3,4-oxadiazol-2-yl]-1H-pyrazol-4-yl]methyl]-1-methyl-  
(CA INDEX NAME)




RN 1016555-30-8 CAPLUS

CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA  
INDEX NAME)



RN 1016555-32-0 CAPLUS

CN 1,3,4-Thiadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX  
NAME)




RN 1016555-34-2 CAPLUS


CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-cyclobutyl- (CA INDEX NAME)

McIntosh

PAGE 1-A




PAGE 2-A




RN 1016555-36-4 CAPLUS

CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-cyclohexyl- (CA INDEX NAME)



RN 1016555-37-5 CAPLUS


CN 1,3,4-Thiadiazole, 2-[1-(4-chlorophenyl)cyclopropyl]-5-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1016555-39-7 CAPLUS

CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-phenylcyclopropyl)- (CA INDEX NAME)


10/529,895



RN 1016555-41-1 CAPLUS  
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(4-methylphenyl)cyclopropyl]- (CA INDEX NAME)




RN 1016555-43-3 CAPLUS  
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(4-methoxyphenyl)cyclopropyl]- (CA INDEX NAME)




RN 1016555-44-4 CAPLUS  
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(2,4-dichlorophenyl)cyclopropyl]- (CA INDEX NAME)

McIntosh

10/529,895




RN 1016555-45-5 CAPLUS  
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclopropyl]- (CA INDEX NAME)




RN 1016555-47-7 CAPLUS  
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclobutyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




RN 1016555-49-9 CAPLUS  
CN 1,3,4-Thiadiazole, 2-[1-(4-chlorophenyl)cyclobutyl]-5-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)

McIntosh


10/529,895

(CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1016555-51-3 CAPLUS  
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-phenylcyclopentyl)- (CA INDEX NAME)




RN 1016555-52-4 CAPLUS  
CN 1,3,4-Thiadiazole, 2-[1-(4-chlorophenyl)cyclopentyl]-5-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)


10/529,895



RN 1016555-53-5 CAPLUS  
CN 1,3,4-Thiadiazole, 2-[5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-(1H-  
1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-methylcyclopropyl)- (CA  
INDEX NAME)




RN 1016555-55-7 CAPLUS  
CN 1,3,4-Thiadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-  
triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(trifluoromethyl)cyclopropyl]-  
(CA INDEX NAME)




RN 1016555-56-8 CAPLUS  
CN 1,3,4-Thiadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-  
triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-[1-(4-chlorophenyl)cyclopropyl]-  
(CA INDEX NAME)

McIntosh


10/529,895



RN 1016555-58-0 CAPLUS  
CN 1,3,4-Thiadiazole, 2-[1-(2-chlorophenyl)-5-(4-chlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 1016557-46-2 CAPLUS  
CN 1,3,4-Oxadiazole, 2-[5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-(1H-1,2,4-triazol-1-ylmethyl)-1H-pyrazol-3-yl]-5-(1-methylcyclopropyl)- (CA INDEX NAME)




L4 ANSWER 3 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2007:1177863 CAPLUS  
DN 147:469247  
TI Preparation of quinolones derivatives useful as inducible nitric oxide synthase inhibitors  
IN Roppe, Jeffrey R.; Bonnefous, Celine; Smith, Nicholas D.; Lindstrom, Andrew K.; Noble, Stewart A.; Hassig, Christian A.; Payne, Joseph E.; Zhuang, Hui; Chen, Xiaohong; Duron, Sergio G.  
PA Kalypsys, Inc., USA  
SO PCT Int. Appl., 238pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

McIntosh

PI	WO 2007117778	A2	20071018	WO 2007-US62769	20070223
	WO 2007117778	A3	20080207		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA US 20080139558 A1 20080612 US 2007-678572 20070223 PRAI US 2006-776561P P 20060224 US 2006-848696P P 20061002 OS MARPAT 147:469247 GI				




AB The invention relates to novel quinolones of formula I [R1 = (un)substituted acyl, alkyl, alkylene, aminoalkyl, amidoalkyl, alkynyl, aryl, arylalkyl, arylalkoxy, etc.; R2 = (un)substituted acyl, alkoxy, alkoxyalkyl, alkyl, alkylene, alkylamino, alkynyl, alkylimino, etc.; R2 may combine with R1 to form (un)substituted heterocycloalkyl; R3 = H, NH2, (un)substituted aryl, haloalkyl, (hetero)arylalkyl, (hetero)(cyclo)alkyl; A, B, C and D independently = (un)substituted acyl, alkoxy, alkyl, alkylene, alkylamino, alkynyl, etc.; any two or more A, B, C and D may combine to form aryl, cycloalkyl, heteroaryl or heterocycloalkyl], and their pharmaceutically acceptable salts, esters or prodrugs, are prepared and disclosed as inducible nitric oxide synthase (iNOS) inhibitors. Thus, e.g. II was prepared by acylation of aniline with Et 3-oxobutanoate followed by bromination and cyclization to generate intermediate 4-(bromomethyl)quinolin-2(1H)-one, which underwent substitution with aniline and acylation with furan-2-carbonyl chloride to provide II. The inhibitory activity of all exemplary compds. was evaluated in DAN assay and II was found to have EC50 value of  $\leq 5 \mu\text{M}$ . I should prove useful for inhibiting or modulating nitric oxide synthase and/or lowering nitric oxide levels of iNOS and for the treatment of an iNOS-mediated disease in a patient in need thereof.

IT 953068-15-0P, 4-[[3-(3-Chlorophenyl)-5-(4-methylthiazol-5-yl)-1H-pyrazol-4-yl]methyl]-8-fluoroquinolin-2(1H)-one  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of quinolones derivs. useful as inducible nitric oxide synthase inhibitors)

RN 953068-15-0 CAPLUS


CN 2(1H)-Quinolone, 4-[[3-(3-chlorophenyl)-5-(4-methyl-5-thiazolyl)-1H-pyrazol-4-yl]methyl]-8-fluoro- (CA INDEX NAME)



L4 ANSWER 4 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2007:744384 CAPLUS  
 DN 148:483659  
 TI Bis( $\mu$ -4-benzyl-3,5-diphenylpyrazolato- $\kappa$ 2N:N')bis[(4,4'-dimethyl-2,2'-bipyridine- $\kappa$ 2N,N')]palladium(II)] bis(hexafluorophosphate) diethyl ether monosolvate monohydrate  
 AU Huang, Hai-Ping; Liu, Li-Xia  
 CS Laboratory for Self-Assembly Chemistry, Department of Chemistry, Renmin University of China, Beijing, 100872, Peop. Rep. China  
 SO Acta Crystallographica, Section E: Structure Reports Online (2007), E63(7), m1875-m1876  
 CODEN: ACSEBH; ISSN: 1600-5368  
 URL: <http://journals.iucr.org/e/issues/2007/07/00/si2018/si2018.pdf>  
 PB Blackwell Publishing Ltd.  
 DT Journal; (online computer file)  
 LA English  
 AB In the crystal structure of the title compound, [Pd<sub>2</sub>(C<sub>22</sub>H<sub>17</sub>N<sub>2</sub>)<sub>2</sub>(C<sub>12</sub>H<sub>12</sub>N<sub>2</sub>)<sub>2</sub>](PF<sub>6</sub>)<sub>2</sub>·C<sub>4</sub>H<sub>10</sub>O·H<sub>2</sub>O, two Pd(dmbpy) units (dmbpy is 4,4'-dimethyl-2,2'-bipyridine) are bridged by 4-benzyl-3,5-diphenylpyrazolate ligands in an exodentate fashion, which results in a clip-like cavity between the two Pd(dmbpy)Pd planes. A disordered hexafluoridophosphate anion is held in the cavity by an anion- $\pi$  interaction [P-F...Cg1 = 3.435(15) Å (Cg1 is the centroid of the Pd-dmbpy chelate ring system) and P-F...Cg2 = 3.187(15) Å (Cg2 is the centroid of a pyridine ring)]. A crystallog. 2-fold rotation axis passes through an F atom of the disordered anion and the mid-point of the two Pd atoms. The P and two F atoms of the 2nd anion also lie on a 2-fold rotation axis, as do the O atom of the Et<sub>2</sub>O and the water O atom. The crystal structure is stabilized by electrostatic forces between the cations and anions, and intermol. H bonds involving hexafluoridophosphate anions (C-H...F), the solvent Et<sub>2</sub>O mols. and H<sub>2</sub>O mols. (C-H...O). Crystallog. data and atomic coordinates are given.  
 IT 1020667-43-9P  
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation) (crystal structure of)  
 RN 1020667-43-9 CAPLUS  
 CN INDEX NAME NOT YET ASSIGNED

CM 1

CRN 60-29-7  
 CMF C4 H10 O




CM 2

CRN 1020667-42-8  
 CMF C68 H58 N8 Pd2 . 2 F6 P

CM 3


10/529,895

CRN 1020667-41-7  
CMF C68 H58 N8 Pd2  
CCI CCS




CM 4

CRN 16919-18-9  
CMF F6 P  
CCI CCS



IT 955955-05-2  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction of palladium dimethylbipyridine nitrato complex with  
benzylidiphenylpyrazole in aqueous solution followed by addition of potassium  
hexafluorophosphate)  
RN 955955-05-2 CAPLUS  
CN 1H-Pyrazole, 3,5-diphenyl-4-(phenylmethyl)- (CA INDEX NAME)




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2007:626543 CAPLUS  
DN 148:296308  
TI 4-[(3,5-Diphenyl-1H-pyrazol-4-yl)methyl]benzonitrile ethanol hemisolvate  
AU Yu, Mei  
CS Institute of Biomedical Engineering, Chinese Academy of Medical Sciences,  
Tianjin, 300192, Peop. Rep. China  
SO Acta Crystallographica, Section E: Structure Reports Online (2007),  
E63(6), o2863  
CODEN: ACSEBH; ISSN: 1600-5368

McIntosh

10/529,895

URL: <http://journals.iucr.org/e/issues/2007/06/00/hg2234/hg2234.pdf>  
PB Blackwell Publishing Ltd.  
DT Journal; (online computer file)  
LA English  
AB In 4-[(3,5-diphenyl-1H-pyrazol-4-yl)methyl]benzonitrile hemiethanolate, C<sub>23</sub>H<sub>17</sub>N<sub>3</sub>·0.5C<sub>2</sub>H<sub>6</sub>O, 2 pyrazole mols. are bridged by 1 EtOH mol. through N-H...O and O-H...N H bonds. The EtOH solvent mol. is located on a mirror plane. These trimol. units are linked by C-H...N, N-H...O and H bonds involving the nitrile groups and EtOH OH as acceptors and C-H...π stacking interactions between Ph groups. Crystallog. data are given.  
IT 1007840-65-4  
RL: PRP (Properties)  
(crystal and mol. structure of)  
RN 1007840-65-4 CAPLUS  
CN Benzonitrile, 4-[(3,5-diphenyl-1H-pyrazol-4-yl)methyl]-, compd. with ethanol (2:1) (CA INDEX NAME)  
  
CM 1  
  
CRN 1007840-64-3  
CMF C23 H17 N3



CM 2  
  
CRN 64-17-5  
CMF C2 H6 O

H<sub>3</sub>C-CH<sub>2</sub>-OH


RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2007:242471 CAPLUS  
DN 147:511993  
TI 4-Benzyl-3,5-diphenyl-1H-pyrazole  
AU Huang, Hai-Ping; Wu, Qiong; Liu, Li-Xia; Sun, Qing-Fu  
CS Laboratory for Self-Assembly Chemistry, Department of Chemistry, Renmin University of China, Beijing, 100872, Peop. Rep. China  
SO Acta Crystallographica, Section E: Structure Reports Online (2007), E63(3), o1473-o1474  
CODEN: ACSEBH; ISSN: 1600-5368  
URL: <http://journals.iucr.org/e/issues/2007/03/00/hg2185/hg2185.pdf>  
PB Blackwell Publishing Ltd.  
DT Journal; (online computer file)  
LA English  
OS CASREACT 147:511993  
AB The mols. of 4-benzyl-3,5-diphenyl-1H-pyrazole, C<sub>22</sub>H<sub>18</sub>N<sub>2</sub>, are connected by N-H...N H bonds, forming cyclic dimers. These dimers are linked by C-H...π H bonds involving the Ph rings as acceptors. Crystallog. data are given.  
IT 955955-05-2P

McIntosh

10/529,895


RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)  
(preparation and crystal and mol. structure of)  
RN 955955-05-2 CAPLUS  
CN 1H-Pyrazole, 3,5-diphenyl-4-(phenylmethyl)- (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2007:36895 CAPLUS  
DN 146:142641  
TI Preparation of substituted 1-sulfolanyl-1H-pyrazoles as anti-AIDS agents  
IN Paessens, Arnold; Schohe-Loop, Rudolf; Bauser, Marcus; Jeske, Mario;  
Koebberling, Johannes; Henninger, Kerstin; Lang, Dieter; Welker, Reinhold;  
Paulsen, Daniela  
PA Aicuris G.m.b.H. & Co. K.-G., Germany  
SO PCT Int. Appl., 94pp.  
CODEN: PIXXD2  
DT Patent  
LA German  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007003389	A2	20070111	WO 2006-EP6430	20060701
	WO 2007003389	A3	20070419		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	DE 102005031580	A1	20070111	DE 2005-102005031580	20050706
PRAI	DE 2005-102005031580	A	20050706		
OS	MARPAT 146:142641				
GI					



AB The title compds. [I; R1, R2 = (substituted) Ph, 5-6 membered heteroaryl;  
R3 = (substituted) Ph, 5-10 heteroaryl] were prepared Thus,

McIntosh

10/529,895

3-[[[1-(1,1-dioxidotetrahydro-3-thienyl)-5-phenyl-3-pyridin-2-yl-1H-pyrazol-4-yl]methyl]benzoic acid (preparation given) in DMF was stirred with 4-aminopyridine, HATU and Et<sub>3</sub>N for 2 h at room temperature to give 46% 3-[[[1-(1,1-dioxidotetrahydro-3-thienyl)-5-phenyl-3-pyridin-2-yl-1H-pyrazol-4-yl]methyl]-N-pyridin-4-ylbenzamide. The latter protected H9 cells from HIV-induced destruction with IC<sub>50</sub> = 0.05  $\mu$ M at 2% FCS.


IT 919095-57-1P

RL: BYP (Byproduct); PREP (Preparation)

(preparation of substituted sulfolanylpurazoles as anti-AIDS agents)

RN 919095-57-1 CAPLUS

CN Benzoic acid, 3-[[[3-(5-chloro-2-thienyl)-5-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-, methyl ester (CA INDEX NAME)



IT 919095-64-0P 919095-65-1P 919095-66-2P

919095-67-3P 919095-68-4P 919095-69-5P

919095-70-8P 919095-71-9P 919095-72-0P

919095-73-1P 919095-74-2P 919095-75-3P

919095-76-4P 919095-77-5P 919095-78-6P

919095-79-7P 919095-80-0P 919095-81-1P

919095-82-2P 919095-83-3P 919095-84-4P

919095-85-5P 919095-86-6P 919095-87-7P

919095-88-8P 919095-89-9P 919095-90-2P

919095-91-3P 919095-92-4P 919095-93-5P

919095-94-6P 919095-95-7P 919095-96-8P

919095-97-9P 919095-98-0P 919095-99-1P

919096-00-7P 919096-01-8P 919096-03-0P

919096-05-2P 919096-07-4P 919096-09-6P

919096-11-0P 919096-13-2P 919096-15-4P

919096-16-5P 919096-18-7P 919096-19-8P

919096-20-1P 919096-21-2P 919096-22-3P


919096-23-4P 919096-24-5P 919096-64-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted sulfolanylpurazoles as anti-AIDS agents)

RN 919095-64-0 CAPLUS

CN Benzamide, 3-[[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-4-pyridinyl- (CA INDEX NAME)




RN 919095-65-1 CAPLUS

McIntosh


10/529,895

CN Benzamide, N-(2-chlorophenyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




RN 919095-66-2 CAPLUS

CN Benzamide, N-(3-methylphenyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-67-3 CAPLUS

CN Benzamide, N-(3-chlorophenyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




RN 919095-68-4 CAPLUS

CN Benzamide, 3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-2-pyridinyl- (CA INDEX NAME)


McIntosh

10/529,895




RN 919095-69-5 CAPLUS

CN Benzamide, N-phenyl-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-70-8 CAPLUS


CN Benzamide, 3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-3-pyridinyl- (CA INDEX NAME)



RN 919095-71-9 CAPLUS


CN Benzamide, N-(2-methyl-4-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)

10/529,895




RN 919095-72-0 CAPLUS

CN Benzamide, 3-[[5-(5-chloro-2-thienyl)-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-2-pyridinyl- (CA INDEX NAME)



RN 919095-73-1 CAPLUS

CN Benzamide, 3-[[5-(5-chloro-2-thienyl)-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-3-pyridinyl- (CA INDEX NAME)




RN 919095-74-2 CAPLUS

CN Benzamide, 3-[[5-(5-chloro-2-thienyl)-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-4-pyridinyl- (CA INDEX NAME)


McIntosh

10/529,895




RN 919095-75-3 CAPLUS

CN Benzamide, 3-[[5-(5-chloro-2-thienyl)-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-(2-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 919095-76-4 CAPLUS

CN Benzamide, 3-[[5-(5-chloro-2-thienyl)-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-(2,6-dimethyl-4-pyridinyl)- (CA INDEX NAME)




McIntosh

10/529,895


RN 919095-77-5 CAPLUS

CN Benzamide, 3-[[5-(2-furanyl)-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-2-pyridinyl- (CA INDEX NAME)




RN 919095-78-6 CAPLUS

CN Benzamide, 3-[[5-(2-furanyl)-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-3-pyridinyl- (CA INDEX NAME)



RN 919095-79-7 CAPLUS

CN Benzamide, 3-[[5-(2-furanyl)-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-4-pyridinyl- (CA INDEX NAME)




McIntosh

10/529,895


RN 919095-80-0 CAPLUS

CN Benzamide, 3-[[5-(2-furanyl)-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-(2-methyl-4-pyridinyl)- (CA INDEX NAME)



RN 919095-81-1 CAPLUS


CN Benzamide, 3-[[3-(5-chloro-2-thienyl)-5-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-2-pyridinyl- (CA INDEX NAME)



RN 919095-82-2 CAPLUS


CN Benzamide, 3-[[3-(5-chloro-2-thienyl)-5-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-3-pyridinyl- (CA INDEX NAME)

10/529,895



RN 919095-83-3 CAPLUS


CN Benzamide, 3-[[3-(5-chloro-2-thienyl)-5-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-4-pyridinyl- (CA INDEX NAME)




RN 919095-84-4 CAPLUS

CN Benzamide, 3-[[3-(5-chloro-2-thienyl)-5-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-(2-methyl-4-pyridinyl)- (CA INDEX NAME)


10/529,895



RN 919095-85-5 CAPLUS  
CN Benzamide, N-1H-benzimidazol-6-yl-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxo-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




RN 919095-86-6 CAPLUS  
CN Benzamide, N-1H-benzotriazol-6-yl-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxo-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-87-7 CAPLUS  
CN Benzamide, N-(5-methyl-3-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxo-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)


McIntosh

10/529,895




RN 919095-88-8 CAPLUS

CN Benzamide, N-1H-indazol-6-yl-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-89-9 CAPLUS


CN Benzamide, N-(6-ethyl-2-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




RN 919095-90-2 CAPLUS

CN Benzamide, N-(6-fluoro-5-methyl-3-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)


10/529,895



RN 919095-91-3 CAPLUS  
CN Benzamide, N-(5-methyl-2-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




RN 919095-92-4 CAPLUS  
CN Benzamide, 3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-2-thiazolyl- (CA INDEX NAME)




RN 919095-93-5 CAPLUS  
CN Benzamide, N-(5-chloro-2-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)


10/529,895




RN 919095-94-6 CAPLUS  
CN Benzamide, N-(2-ethyl-4-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-95-7 CAPLUS  
CN Benzamide, N-(4-methyl-2-thiazolyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-96-8 CAPLUS  
CN Benzamide, N-(5-methyl-2-thiazolyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




RN 919095-97-9 CAPLUS

McIntosh


10/529,895

CN Benzamide, N-1H-indazol-7-yl-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




RN 919095-98-0 CAPLUS

CN Benzamide, N-(6-methoxy-3-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-99-1 CAPLUS

CN Benzamide, N-(6-amino-2-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




RN 919096-00-7 CAPLUS

CN Benzamide, N-(1-oxido-2-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)


McIntosh

10/529,895




RN 919096-01-8 CAPLUS

CN Benzamide, 3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-4-pyrimidinyl- (CA INDEX NAME)



RN 919096-03-0 CAPLUS

CN Benzamide, 3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-N-2-pyrazinyl- (CA INDEX NAME)




RN 919096-05-2 CAPLUS


CN Benzamide, N-(6-methyl-2-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)

McIntosh


10/529,895



RN 919096-07-4 CAPLUS  
CN Benzamide, N-(5-fluoro-2-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




RN 919096-09-6 CAPLUS  
CN Benzamide, N-[1-(methoxymethyl)-1H-pyrazol-4-yl]-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




RN 919096-11-0 CAPLUS  
CN Benzamide, N-(4-methyl-2-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)


10/529,895




RN 919096-13-2 CAPLUS  
CN Benzamide, N-(4-ethyl-2-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919096-15-4 CAPLUS  
CN Benzamide, N-(5-methyl-1,3,4-thiadiazol-2-yl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919096-16-5 CAPLUS  
CN Benzamide, N-(4,6-dimethyl-2-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




McIntosh

10/529,895


RN 919096-18-7 CAPLUS

CN Benzamide, N-[5-(hydroxymethyl)-1,3,4-thiadiazol-2-yl]-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




RN 919096-19-8 CAPLUS

CN Benzamide, N-(4,5-dimethyl-2-oxazolyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919096-20-1 CAPLUS

CN Benzamide, N-(1,3-dimethyl-1H-pyrazol-5-yl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




RN 919096-21-2 CAPLUS

CN Benzamide, N-(5-ethyl-1,3,4-thiadiazol-2-yl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)


McIntosh

10/529,895




RN 919096-22-3 CAPLUS

CN Benzamide, N-1H-indol-4-yl-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919096-23-4 CAPLUS

CN Benzamide, N-(2,6-dimethyl-4-pyrimidinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




RN 919096-24-5 CAPLUS


CN Benzamide, N-(3-methyl-5-isoxazolyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)

McIntosh


10/529,895



RN 919096-64-3 CAPLUS  
CN Benzamide, N-(6-chloro-3-pyridinyl)-3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




IT 919095-54-8P 919095-55-9P 919095-56-0P  
919095-58-2P 919095-59-3P 919095-60-6P  
919095-61-7P 919095-62-8P 919095-63-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of substituted sulfolanylpurazoles as anti-AIDS agents)  
RN 919095-54-8 CAPLUS  
CN Benzoic acid, 3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-, methyl ester (CA INDEX NAME)



RN 919095-55-9 CAPLUS  
CN Benzoic acid, 3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)


McIntosh

10/529,895




RN 919095-56-0 CAPLUS

CN Benzoic acid, 3-[[5-(5-chloro-2-thienyl)-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-, methyl ester (CA INDEX NAME)




RN 919095-58-2 CAPLUS

CN Benzoic acid, 3-[[3-(2-furanyl)-5-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-, methyl ester (CA INDEX NAME)



RN 919095-59-3 CAPLUS

CN Benzoic acid, 3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



McIntosh

10/529,895


RN 919095-60-6 CAPLUS

CN Benzoic acid, 3-[[5-phenyl-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 919095-59-3


CMF C26 H23 N3 O4 S



CM 2


CRN 76-05-1

CMF C2 H F3 O2




RN 919095-61-7 CAPLUS

CN Benzoic acid, 3-[[3-(5-chloro-2-thienyl)-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



RN 919095-62-8 CAPLUS

CN Benzoic acid, 3-[[3-(5-chloro-2-thienyl)-5-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)




McIntosh

10/529,895

RN 919095-63-9 CAPLUS

CN Benzoic acid, 3-[[5-(2-furanyl)-3-(2-pyridinyl)-1-(tetrahydro-1,1-dioxido-3-thienyl)-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)



L4 ANSWER 8 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:661832 CAPLUS

DN 145:292940

TI Synthesis of pyrazoles by treatment of 3-benzylchromones, 3-benzylflavones and their 4-thio analogues with hydrazine

AU Levai, Albert; Silva, Artur M. S.; Cavaleiro, Jose A. S.; Alkorta, Ibon; Elguero, Jose; Jeko, Jozsef

CS Department of Organic Chemistry, University of Debrecen, Debrecen, 4010, Hung.

SO European Journal of Organic Chemistry (2006), (12), 2825-2832

CODEN: EJOCFK; ISSN: 1434-193X

PB Wiley-VCH Verlag GmbH & Co. KGaA

DT Journal

LA English

OS CASREACT 145:292940

AB The synthesis of pyrazoles has been accomplished by treatment of 3-benzylchromones, 3-benzylflavones and their 4-thio analogs with hydrazine hydrate in hot pyridine. A plausible reaction mechanism for the formation of pyrazoles was discussed. A <sup>1</sup>H NMR study in [D<sub>6</sub>]DMSO allowed the presence of both pyrazole annular tautomers to be observed, due to the presence of intramol. hydrogen bonds in each tautomer (OH--N and NH--O). GIAO/B3LYP/6-311++G\*\* calcns. were carried out on some model pyrazoles to provide a theor. basis for the NMR exptl. observations.

IT 908252-19-7P 908252-20-0P 908252-21-1P

908252-23-3P 908252-24-4P 908252-25-5P



908252-26-6P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of substituted pyrazoles via heterocyclization of benzylchromones and benzothiochromones with hydrazine)

RN 908252-19-7 CAPLUS


CN Phenol, 2-[4-[(2-chlorophenyl)methyl]-5-phenyl-1H-pyrazol-3-yl]- (CA INDEX NAME)



10/529,895


RN 908252-20-0 CAPLUS

CN Phenol, 2-[4-[(3-chlorophenyl)methyl]-5-phenyl-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 908252-21-1 CAPLUS

CN Phenol, 2-[4-[(4-chlorophenyl)methyl]-5-phenyl-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 908252-23-3 CAPLUS


CN Phenol, 2-[4-[(4-bromophenyl)methyl]-5-phenyl-1H-pyrazol-3-yl]- (CA INDEX NAME)





RN 908252-24-4 CAPLUS

CN Phenol, 2-[4-[(4-nitrophenyl)methyl]-5-phenyl-1H-pyrazol-3-yl]- (CA INDEX NAME)


10/529,895



RN 908252-25-5 CAPLUS  
CN Phenol, 2-[4-[(2,4-dichlorophenyl)methyl]-5-phenyl-1H-pyrazol-3-yl]- (CA  
INDEX NAME)



RN 908252-26-6 CAPLUS  
CN Phenol, 2-[4-[(3,4-dichlorophenyl)methyl]-5-phenyl-1H-pyrazol-3-yl]- (CA  
INDEX NAME)






RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2005:219796 CAPLUS  
DN 142:280203  
TI Preparation of bicyclic pyrazole derivatives as dipeptidyl peptidase IV  
(DPP-IV) inhibitors  
IN Nakahira, Hiroyuki; Hochigai, Hitoshi; Takeda, Tatsuya; Kobayashi,  
Tomonori; Hume, William Ewan

McIntosh

PA Sumitomo Pharmaceuticals Co., Ltd., Japan  
 SO PCT Int. Appl., 252 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005021550	A1	20050310	WO 2004-JP12617	20040825
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1659123	A1	20060524	EP 2004-772573	20040825
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
	US 20070082908	A1	20070412	US 2006-595125	20060227
PRAI	JP 2003-306948	A	20030829		
	WO 2004-JP12617	W	20040825		
OS	MARPAT 142:280203				
GI					



AB The title compds. I [R1 represents hydrogen, optionally substituted alkyl, etc.; the solid line and dotted line between A and A1 represent a double bond or a single bond; A represents a group represented by the formula C(R2), etc.; A1 represents a group represented by the formula C(R4), etc.; R2 represents hydrogen, optionally substituted alkyl, etc.; R4 represents hydrogen, optionally substituted alkyl, etc.; R6 represents hydrogen, optionally substituted aryl, etc.; and Y represents, e.g., a group represented by the formula Q1 (wherein A' represents (CH2)m1; m1 is 0, 1, 2, or 3; and R7 is absent, or one or two R7's are present and each independently represents optionally substituted alkyl, etc.).] are prepared Et 3-(but-2-yn-1-yl)-4-oxo-2-(piperazin-1-yl)-4,5-dihydropyrazolo[1,5-a]pyrazine-6-carboxylate hydrochloride was prepared by heating a solution of II in 1,4-dioxane containing HCl and water at 50°C for 2.5 h. Compds. of this invention in vitro showed IC50 values of 0.9 nM to 82 nM against human DPP-IV.

IT 847492-77-7P 847492-78-8P 847492-79-9P  
 847492-80-2P 847492-81-3P 847492-82-4P

10/529,895

847492-83-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of bicyclic pyrazole derivs. as dipeptidyl peptidase IV  
inhibitors)

RN 847492-77-7 CAPLUS

CN L-Proline, 1-[[4-[(2-chlorophenyl)methyl]-5-[(3R)-3-[[1,1-  
dimethylethoxy)carbonyl]amino]-1-piperidinyl]-1-(methoxymethyl)-1H-pyrazol-  
3-yl]carbonyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 847492-78-8 CAPLUS

CN L-Proline, 1-[[4-[(2-chlorophenyl)methyl]-5-[(3R)-3-[[1,1-  
dimethylethoxy)carbonyl]amino]-1-piperidinyl]-1-(methoxymethyl)-1H-pyrazol-  
3-yl]carbonyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 847492-79-9 CAPLUS

CN Carbamic acid, [(3R)-1-[4-[(2-chlorophenyl)methyl]-1-(methoxymethyl)-3-[[2-  
[(methoxymethylamino)carbonyl]-1-pyrrolidinyl]carbonyl]-1H-pyrazol-5-yl]-3-  
piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/529,895

RN 847492-80-2 CAPLUS

CN Carbamic acid, [(3R)-1-[3-[(2-acetyl-1-pyrrolidinyl)carbonyl]-4-[(2-chlorophenyl)methyl]-1-(methoxymethyl)-1H-pyrazol-5-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847492-81-3 CAPLUS

CN L-Proline, 1-[[4-[(2-chlorophenyl)methyl]-5-[(3R)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidinyl]-1-(methoxymethyl)-1H-pyrazol-3-yl]carbonyl]-4-fluoro-, methyl ester, (4S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 847492-82-4 CAPLUS

CN L-Proline, 1-[[4-[(2-chlorophenyl)methyl]-5-[(3R)-3-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-piperidinyl]-1-(methoxymethyl)-1H-pyrazol-3-yl]carbonyl]-4-fluoro-, (4S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 847492-83-5 CAPLUS

CN Carbamic acid, [(3R)-1-[4-[(2-chlorophenyl)methyl]-3-[[[(2S,4S)-4-fluoro-2-[(methoxymethylamino)carbonyl]-1-pyrrolidinyl]carbonyl]-1-(methoxymethyl)-1H-pyrazol-5-yl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

McIntosh



Absolute stereochemistry.



L4 ANSWER 10 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2004:1156566 CAPLUS  
DN 142:94061  
TI Preparation of pyrazole glycoside compounds as SGLT inhibitors  
IN Kikuchi, Norihiko; Fujikura, Hideki; Tazawa, Shigeki; Yamato, Tokuhisa;  
Isaji, Masayuki  
PA Kissei Pharmaceutical Co., Ltd., Japan  
SO PCT Int. Appl., 105 pp.  
CODEN: PIXXD2  
DT Patent  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004113359	A1	20041229	WO 2004-JP8695	20040615
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2529878	A1	20041229	CA 2004-2529878	20040615
EP	1637539	A1	20060322	EP 2004-746165	20040615
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	US 20070060531	A1	20070315	US 2006-561217	20061113
PRAI	JP 2003-175663	A	20030620		
	WO 2004-JP8695	W	20040615		
OS	MARPAT 142:94061				
GI					

McIntosh




AB Title compds. I [R1 = H, (un)substituted alkyl, etc.; one of Q and T is II, etc.; the other is Z-Ar; Z = O, etc.; Ar = aryl, etc.; R = (un)substituted cycloalkyl, etc.] were prepared For example, glycosidation of 1-isopropyl-4-(4-methoxybenzyl)-5-phenoxy-1,2-dihydro-3H-pyrazol-3-one by 2,3,4,6-tetra-O-acetyl- $\beta$ -D-glucopyranosyl bromide in the presence of benzyltributylammonium chloride followed by deacetylation using sodium methoxide afforded compound I [R1 = isopropyl; R = 4-methoxyphenyl; Q = phenoxy; T = II]. In SMINT inhibition assays, the IC50 value of compound I [R1 = isopropyl; R = 4-methoxyphenyl; Q = phenoxy; T = II] was 700 nM. Of note, compds. I have SGLT inhibition activity (no data provided). Compds. I are claimed useful for the treatment of diabetes, obesity, etc.

IT 815581-51-2P 815581-53-4P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of pyrazole glycoside compds. as SGLT inhibitors for treatment of diabetes and obesity)


RN 815581-51-2 CAPLUS  
 CN  $\beta$ -D-Glucopyranoside, 4'-[(2,4-dimethoxyphenyl)methyl]-1'-(1-methylethyl)-5-(1-piperidinyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 815581-53-4 CAPLUS  
 CN  $\beta$ -D-Glucopyranoside, 4'-[(2,4-dimethoxyphenyl)methyl]-1'-(1-methylethyl)[1,5'-bi-1H-pyrazol]-3'-yl (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:486406 CAPLUS

DN 141:47334

TI Preventive or remedy for diseases caused by hyperglycemia

IN Ito, Fumiaki; Shibazaki, Toshihide; Tomae, Masaki; Fushimi, Nobuhiko;  
Isaji, Masayuki

PA Kissei Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004050122	A1	20040617	WO 2003-JP15503	20031204
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2507665	A1	20040617	CA 2003-2507665	20031204
AU 2003289156	A1	20040623	AU 2003-289156	20031204
EP 1568380	A1	20050831	EP 2003-777222	20031204
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
CN 1744916	A	20060308	CN 2003-80109504	20031204
US 20060035844	A1	20060216	US 2005-537495	20050603
IN 2005DN02385	A	20070105	IN 2005-DN2385	20050603
PRAI JP 2002-352201	A	20021204		
WO 2003-JP15503	W	20031204		

AB It is intended to provide a medicinal composition containing as the active ingredient a selective SGLT1 inhibitor (for example, an SGLT1 inhibitor substantially showing no GLUT2 and/or GLUT5 inhibitory effect) which exerts a sugar absorption inhibitory effect over a wide range, also has a hypoglycemic effect caused by fructose intake in usual diet and thus can show an outstanding hypoglycemic effect and which is appropriate as a preventive or a remedy for diseases caused by hyperglycemia (for example, diabetes, impaired glucose tolerance, diabetic complications or obesity).

IT 705445-35-8P, 3-( $\beta$ -D-Glucopyranosyloxy)-4-[[4-(2-guanidinoethoxy)-2-methylphenyl]methyl]-5-indolyl-1H-pyrazole  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(SGLT1 inhibitors as preventives or remedies for diseases caused by hyperglycemia)

RN 705445-35-8 CAPLUS

CN Guanidine, [2-[4-[[3-( $\beta$ -D-glucopyranosyloxy)-5-(1H-indol-1-yl)-1H-pyrazol-4-yl]methyl]-3-methylphenoxy]ethyl]- (9CI) (CA INDEX NAME)


10/529,895

Absolute stereochemistry.



IT 705445-15-4P 705445-20-1P 705445-25-6P,  
3-(2,3,4,6-Tetra-O-acetyl- $\beta$ -D-glucopyranosyloxy)-4-[[4-(2-acetoxyethoxy)-2-methylphenyl]methyl]-5-indolyl-1H-pyrazole  
705445-30-3P 705445-45-0P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(SGLT1 inhibitors as preventives or remedies for diseases caused by  
hyperglycemia)  
RN 705445-15-4 CAPLUS  
CN  $\beta$ -D-Glucopyranoside, 5-(1H-indol-1-yl)-4-[[2-methyl-4-[2-(phenylmethoxy)ethoxy]phenyl]methyl]-1H-pyrazol-3-yl, 2,3,4,6-tetraacetate  
(CA INDEX NAME)

Absolute stereochemistry.




RN 705445-20-1 CAPLUS  
CN  $\beta$ -D-Glucopyranoside, 4-[[4-(2-hydroxyethoxy)-2-methylphenyl]methyl]-5-(1H-indol-1-yl)-1H-pyrazol-3-yl, 2,3,4,6-tetraacetate (CA INDEX NAME)

Absolute stereochemistry.


McIntosh

10/529,895




RN 705445-25-6 CAPLUS  
CN  $\beta$ -D-Glucopyranoside, 4-[[4-[2-(acetyloxy)ethoxy]-2-methylphenyl]methyl]-5-(1H-indol-1-yl)-1H-pyrazol-3-yl, 2,3,4,6-tetraacetate (CA INDEX NAME)

Absolute stereochemistry.



RN 705445-30-3 CAPLUS  
CN  $\beta$ -D-Glucopyranoside, 4-[[4-(2-aminoethoxy)-2-methylphenyl]methyl]-5-(1H-indol-1-yl)-1H-pyrazol-3-yl, 2,3,4,6-tetraacetate (CA INDEX NAME)

Absolute stereochemistry.




RN 705445-45-0 CAPLUS  
CN Carbamic acid, [imino[[2-[4-[[3-(1H-indol-1-yl)-5-[(2,3,4,6-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)oxy]-1H-pyrazol-4-yl]methyl]-3-methylphenyl]methyl]-2-oxoethyl]amino]-1H-imidazole-4-carboxylic acid

McIntosh

10/529,895

methylphenoxy]ethyl]amino]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2004:311011 CAPLUS  
DN 140:321649  
TI Preparation of pyrazolyl glycoside derivatives as inhibitors of  
1,5-anhydroglucitol/fructose/mannose transporters  
IN Fujikura, Hideki; Kikuchi, Norihiko; Tazawa, Shigeki; Yamato, Tokuhisa;  
Isaji, Masayuki  
PA Kissei Pharmaceutical Co., Ltd., Japan  
SO PCT Int. Appl., 159 pp.  
CODEN: PIXXD2  
DT Patent  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004031203	A1	20040415	WO 2003-JP12477	20030930
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2500873	A1	20040415	CA 2003-2500873	20030930
	AU 2003272903	A1	20040423	AU 2003-272903	20030930
	EP 1550668	A1	20050706	EP 2003-753967	20030930
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	US 20060128635	A1	20060615	US 2005-529895	20050919
PRAI	JP 2002-293090	A	20021004		
	JP 2002-330694	A	20021114		
	JP 2002-378959	A	20021227		
	WO 2003-JP12477	W	20030930		
OS	MARPAT 140:321649				
GI					



AB The title compds. [I; R = each (un)substituted C3-8 cycloalkyl, C6-10 aryl, C2-9 heterocycloalkyl, or C1-9 heteroaryl; R1 = H, each (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, C6-10 aryl, C2-9 heterocycloalkyl, or C1-9 heteroaryl; one of Q0 and T0 =  $\alpha$ - or  $\beta$ -D-glucopyranosyloxy or -mannopyranosyloxy or  $\beta$ -D-deoxyglucopyranosyloxy- and the other = (CH<sub>2</sub>)<sub>n</sub>Ar; wherein Ar = each (un)substituted C6-10 aryl or C1-9 heteroaryl; n = an integer of 0-2] or pharmacol. acceptable salts or prodrugs thereof are prepared Also disclosed are medicinal composition containing the compound I, medicinal use thereof, and intermediates in producing the same. These compds. exerts an excellent effect of inhibiting human 1,5-anhydroglucitol/fructose/mannose transporters and inhibit reabsorption or cellular uptake of glucose, fructose, and mannose in kidney or absorption of these saccharide small intestine and inhibit the increase in blood sugar. Therefore, they are useful as preventives, progress inhibitors or remedies for a disease caused by the over intake of at least one saccharide selected from among glucose, fructose, and mannose or a disease caused by hyperglycemia (diabetic complication, diabetes, or diabetic nephropathy). Thus, glycosidation of 1-isopropyl-5-(4-methoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1,2-dihydro-3H-pyrazol-3-one by acetobromo- $\alpha$ -D-glucose in the presence of benzyltributylammonium bromide in a mixture of CH<sub>2</sub>Cl<sub>2</sub> and 5 N aqueous NaOH at room temperature for 1.5 h followed by treatment of the product with NaOMe in MeOH gave 3-( $\beta$ -D-glucopyranosyloxy)-1-isopropyl-5-(4-methoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1H-pyrazole (II). II in vitro inhibited the uptake of [14C]methyl  $\alpha$ -D-glucopyranoside in COS-7 cells transfected with human SMINT/PME18S-FL expression plasmid with IC<sub>50</sub> of 92 nM.

IT 678993-32-3P 678993-33-4P 678993-34-5P  
 678993-35-6P 678993-36-7P 678993-37-8P  
 678993-38-9P 678993-39-0P 678993-40-3P  
 678993-41-4P 678993-42-5P 678993-43-6P  
 678993-44-7P 678993-45-8P 678993-46-9P  
 678993-47-0P 678993-48-1P 678993-49-2P  
 678993-50-5P 678993-51-6P 678993-52-7P  
 678993-53-8P 678993-54-9P 678993-55-0P  
 678993-56-1P 678993-57-2P 678993-58-3P  
 678993-59-4P 678993-60-7P 678993-61-8P  
 678993-62-9P 678993-63-0P 678993-64-1P  
 678993-65-2P 678993-66-3P 678993-67-4P  
 678993-68-5P 678993-69-6P 678993-70-9P  
 678993-71-0P 678993-72-1P 678993-73-2P  
 678993-74-3P 678993-75-4P 678993-76-5P  
 678993-77-6P 678993-78-7P 678993-79-8P  
 678993-80-1P 678993-81-2P 678993-82-3P  
 678993-83-4P 678993-84-5P 678993-85-6P  
 678993-86-7P 678993-87-8P 678993-88-9P  
 678993-89-0P 678993-90-3P 678993-91-4P  
 678993-92-5P 678993-93-6P 678993-94-7P  
 678993-95-8P 678993-96-9P 678993-97-0P  
 678993-98-1P 678993-99-2P 678994-00-8P  
 678994-01-9P 678994-02-0P 678994-03-1P  
 678994-04-2P 678994-05-3P 678994-06-4P  
 678994-07-5P 678994-08-6P 678994-09-7P  
 678994-10-0P 678994-11-1P 678994-12-2P  
 678994-13-3P 678994-14-4P 678994-15-5P

10/529,895

678994-23-5P 678994-24-6P 678994-25-7P  
678994-26-8P 678994-48-4P 678994-49-5P  
678994-50-8P 678994-51-9P 678994-52-0P  
678994-53-1P 678994-54-2P 678994-55-3P  
678994-56-4P 678994-57-5P 678994-58-6P  
678994-59-7P 678994-60-0P 678994-61-1P  
678994-62-2P 678994-63-3P 678994-64-4P  
678994-65-5P 678994-66-6P 678994-67-7P  
678994-68-8P 678994-69-9P 678994-70-2P  
678994-71-3P 678994-72-4P 678994-73-5P  
678994-74-6P 678994-75-7P 678994-76-8P  
678994-77-9P 679392-47-3P 679392-48-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of pyrazolyl glycoside derivs. as inhibitors of  
1,5-anhydroglucitol/fructose/mannose transporters and preventives,  
progress inhibitors or remedies for diabetic complication, diabetes, or  
diabetic nephropathy)

RN 678993-32-3 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(4-methoxyphenyl)-4-[(4-methoxyphenyl)methyl]-  
1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678993-33-4 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 1-(1-methylethyl)-5-phenyl-4-(phenylmethyl)-1H-  
pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-34-5 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-  
phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678993-35-6 CAPLUS

CN β-D-Glucopyranoside, 1-(1,1-dimethylethyl)-5-phenyl-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678993-36-7 CAPLUS

CN β-D-Glucopyranoside, 1-(1,1-dimethylethyl)-4-[(4-methoxyphenyl)methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-37-8 CAPLUS

CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1,5-diphenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678993-38-9 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 1-(4-fluorophenyl)-4-[(4-methoxyphenyl)methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678993-39-0 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 1-cyclohexyl-4-[(4-methoxyphenyl)methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-40-3 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 1-cyclopentyl-4-[(4-methoxyphenyl)methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.


McIntosh

10/529,895




RN 678993-41-4 CAPLUS  
CN β-D-Glucopyranoside, 1,5-diphenyl-4-(phenylmethyl)-1H-pyrazol-3-yl  
(CA INDEX NAME)

Absolute stereochemistry.




RN 678993-42-5 CAPLUS  
CN β-D-Glucopyranoside, 1-(4-fluorophenyl)-5-phenyl-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-43-6 CAPLUS  
CN β-D-Glucopyranoside, 1-cyclopentyl-5-phenyl-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-44-7 CAPLUS

McIntosh

10/529,895

CN  $\beta$ -D-Glucopyranoside, 5-(4-fluorophenyl)-1-(1-methylethyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678993-45-8 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(3-fluorophenyl)-1-(1-methylethyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678993-46-9 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(2-methoxyphenyl)-1-(1-methylethyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678993-47-0 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(3-methoxyphenyl)-1-(1-methylethyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/529,895

RN 678993-48-1 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(4-methoxyphenyl)-1-(1-methylethyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678993-49-2 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(4-fluorophenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678993-50-5 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(3-fluorophenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-51-6 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(3-methoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678993-52-7 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(2-methoxyphenyl)methyl]-1-(1-methylethyl)-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678993-53-8 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(3-methoxyphenyl)methyl]-1-(1-methylethyl)-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-54-9 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 1-(3-fluorophenyl)-5-phenyl-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678993-55-0 CAPLUS

CN β-D-Glucopyranoside, 1-(2-fluorophenyl)-5-phenyl-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678993-56-1 CAPLUS

CN β-D-Glucopyranoside, 1-(3-fluorophenyl)-4-[(4-methoxyphenyl)methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-57-2 CAPLUS

CN β-D-Glucopyranoside, 1-(2-fluorophenyl)-4-[(4-methoxyphenyl)methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678993-58-3 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 1-cyclobutyl-4-[(4-methoxyphenyl)methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678993-59-4 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(2,4-dimethoxyphenyl)methyl]-1-(1-methylethyl)-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-60-7 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 1-(1-methylethyl)-4-(phenylmethyl)-5-[2-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678993-61-8 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 1-(1-methylethyl)-4-(phenylmethyl)-5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678993-62-9 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 1-(1-methylethyl)-4-(phenylmethyl)-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678993-63-0 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(2-fluorophenyl)-1-(1-methylethyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-64-1 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 1-(1-methylethyl)-5-(2-methylphenyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678993-65-2 CAPLUS

CN β-D-Glucopyranoside, 1-(1-methylethyl)-5-(3-methylphenyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678993-66-3 CAPLUS

CN β-D-Glucopyranoside, 1-(1-methylethyl)-5-(4-methylphenyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678993-67-4 CAPLUS

CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-[2-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/529,895

RN 678993-68-5 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-[3-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678993-69-6 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-[4-(trifluoromethyl)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678993-70-9 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-(2-methylphenyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-71-0 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-(3-methylphenyl)-1H-pyrazol-3-yl (CA INDEX NAME)

McIntosh

10/529,895


Absolute stereochemistry.



RN 678993-72-1 CAPLUS

CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-(4-methylphenyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678993-73-2 CAPLUS

CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-5-phenyl-1-propyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-74-3 CAPLUS

CN β-D-Glucopyranoside, 5-(4-ethoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678993-75-4 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-5-[4-(1-methylethoxy)phenyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678993-76-5 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(4-hydroxyphenyl)-1-(1-methylethyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-77-6 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(4-butoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678993-78-7 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-[4-(1-ethylpropoxy)phenyl]-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678993-79-8 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-[4-(cyclopentyloxy)phenyl]-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-80-1 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-[4-(1-methylethoxy)phenyl]-1-(1-methylethyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.


McIntosh

10/529,895




RN 678993-81-2 CAPLUS  
CN β-D-Glucopyranoside, 4-[(4-fluorophenyl)methyl]-5-[4-(1-methylethoxy)phenyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.



RN 678993-82-3 CAPLUS  
CN β-D-Glucopyranoside, 1-ethyl-4-[(4-methoxyphenyl)methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-83-4 CAPLUS  
CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(2-methylpropyl)-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678993-84-5 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(4-fluorophenyl)-4-[(4-fluorophenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678993-85-6 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-[4-(2-methylpropyl)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-86-7 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-(4-pentylphenyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678993-87-8 CAPLUS

CN β-D-Glucopyranoside, 5-(4-butylphenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678993-88-9 CAPLUS

CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-(4-propylphenyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-89-0 CAPLUS

CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-[4-(1-methylethyl)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678993-90-3 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(4-ethylphenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678993-91-4 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(3,4-dimethoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-92-5 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-(1-naphthalenyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678993-93-6 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-(2-naphthalenyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678993-94-7 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(3-fluoro-4-methoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-95-8 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-[1,1'-biphenyl]-4-yl-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678993-96-9 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(4-methoxy-3-methylphenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678993-97-0 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(4-ethoxyphenyl)-4-[(4-fluorophenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678993-98-1 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(4-fluorophenyl)methyl]-1-(1-methylethyl)-5-[(2,2,2-trifluoroethoxy)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678993-99-2 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(4-fluorophenyl)methyl]-5-phenyl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678994-00-8 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-[4-(2,2,2-trifluoroethoxy)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-01-9 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(3-hydroxyphenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678994-02-0 CAPLUS

CN β-D-Glucopyranoside, 5-(2-hydroxyphenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678994-03-1 CAPLUS

CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-[2-(phenylmethoxy)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-04-2 CAPLUS

CN β-D-Glucopyranoside, 4-[[4-(methylthio)phenyl]methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678994-05-3 CAPLUS

CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678994-06-4 CAPLUS

CN β-D-Glucopyranoside, 4-[(4-ethoxyphenyl)methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-07-5 CAPLUS

CN β-D-Glucopyranoside, 5-phenyl-4-[(4-propoxyphenyl)methyl]-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678994-08-6 CAPLUS

CN β-D-Glucopyranoside, 4-[[4-(1-methylethoxy)phenyl]methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678994-09-7 CAPLUS

CN β-D-Glucopyranoside, 4-[(4-butoxyphenyl)methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-10-0 CAPLUS

CN β-D-Glucopyranoside, 4-[(4-ethylphenyl)methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678994-11-1 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-phenyl-4-[(4-propylphenyl)methyl]-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678994-12-2 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[[4-(1-methylethyl)phenyl]methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-13-3 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[[4-(2-methylpropyl)phenyl]methyl]-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678994-14-4 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-([1,1'-biphenyl]-4-ylmethyl)-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678994-15-5 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 1-(1-methylethyl)-5-[4-(phenylmethoxy)phenyl]-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-23-5 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-cyclobutyl-1-(1-methylethyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678994-24-6 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-cyclohexyl-1-(1-methylethyl)-4-(phenylmethyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678994-25-7 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-cyclobutyl-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-26-8 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-cyclohexyl-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.


10/529,895



RN 678994-48-4 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678994-49-5 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(1,3-benzodioxol-5-yl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-50-8 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(3,5-dimethoxyphenyl)methyl]-5-(4-methoxyphenyl)-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678994-51-9 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(2-ethoxy-4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678994-52-0 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(2-ethoxyphenyl)methyl]-1-(1-methylethyl)-5-phenyl-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-53-1 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(4-methoxyphenyl)-4-[(2-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678994-54-2 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(2-ethoxyphenyl)methyl]-5-(4-methoxyphenyl)-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678994-55-3 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(2-ethoxy-4-methoxyphenyl)methyl]-5-(4-methoxyphenyl)-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-56-4 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(2,4-dimethoxyphenyl)methyl]-5-(4-ethylphenyl)-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678994-57-5 CAPLUS

CN β-D-Glucopyranoside, 4-[(2,4-dimethoxyphenyl)methyl]-1-(1-methylethyl)-5-[4-(1-methylethyl)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678994-58-6 CAPLUS

CN β-D-Glucopyranoside, 5-[4-(dimethylamino)phenyl]-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-59-7 CAPLUS

CN β-D-Glucopyranoside, 4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-5-(3-pyridinyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678994-60-0 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(2,4-dimethoxyphenyl)methyl]-5-[4-(dimethylamino)phenyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678994-61-1 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(2,4-dimethoxyphenyl)methyl]-1-(1-methylethyl)-5-(4-pyridinyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-62-2 CAPLUS

CN Benzoic acid, 4-[4-[(2,4-dimethoxyphenyl)methyl]-3-(β-D-glucopyranosyloxy)-1-(1-methylethyl)-1H-pyrazol-5-yl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678994-63-3 CAPLUS

CN Benzoic acid, 4-[4-[(2,4-dimethoxyphenyl)methyl]-3-(β-D-glucopyranosyloxy)-1-(1-methylethyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 678994-64-4 CAPLUS

CN β-D-Glucopyranoside, 4-[(2,4-dimethoxyphenyl)methyl]-1-(1-methylethyl)-5-(3-thienyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-65-5 CAPLUS

CN β-D-Glucopyranoside, 4-[(2,4-dimethoxyphenyl)methyl]-1-(1-methylethyl)-5-(2-thienyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.


McIntosh

10/529,895




RN 678994-66-6 CAPLUS  
CN Benzamide, 4-[4-[(2,4-dimethoxyphenyl)methyl]-3-( $\beta$ -D-glucopyranosyloxy)-1-(1-methylethyl)-1H-pyrazol-5-yl]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 678994-67-7 CAPLUS  
CN Benzamide, 4-[4-[(2,4-dimethoxyphenyl)methyl]-3-( $\beta$ -D-glucopyranosyloxy)-1-(1-methylethyl)-1H-pyrazol-5-yl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-68-8 CAPLUS  
CN Benzamide, 4-[4-[(2,4-dimethoxyphenyl)methyl]-3-( $\beta$ -D-glucopyranosyloxy)-1-(1-methylethyl)-1H-pyrazol-5-yl]- (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678994-69-9 CAPLUS

CN Acetamide, 2-[4-[[3-( $\beta$ -D-glucopyranosyloxy)-5-(4-methoxyphenyl)-1-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methoxyphenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 678994-70-2 CAPLUS

CN Acetamide, 2-[4-[[5-(4-ethylphenyl)-3-( $\beta$ -D-glucopyranosyloxy)-1-(1-methylethyl)-1H-pyrazol-4-yl]methyl]-3-methoxyphenoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-71-3 CAPLUS

CN Acetamide, 2-[4-[[3-( $\beta$ -D-glucopyranosyloxy)-1-(1-methylethyl)-5-[4-(1-methylethyl)phenyl]-1H-pyrazol-4-yl]methyl]-3-methoxyphenoxy]- (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678994-72-4 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[[4-(2-hydroxyethoxy)-2-methoxyphenyl]methyl]-5-(4-methoxyphenyl)-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678994-73-5 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(4-ethylphenyl)-4-[[4-(2-hydroxyethoxy)-2-methoxyphenyl]methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-74-6 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[[4-(2-hydroxyethoxy)-2-methoxyphenyl]methyl]-1-(1-methylethyl)-5-[4-(1-methylethyl)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.

McIntosh


10/529,895



RN 678994-75-7 CAPLUS

CN β-D-Glucopyranoside, 4-[[4-(3-hydroxypropoxy)-2-methoxyphenyl]methyl]-5-(4-methoxyphenyl)-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.



RN 678994-76-8 CAPLUS

CN β-D-Glucopyranoside, 5-(4-ethylphenyl)-4-[[4-(3-hydroxypropoxy)-2-methoxyphenyl]methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl (CA INDEX NAME)

Absolute stereochemistry.




RN 678994-77-9 CAPLUS

CN β-D-Glucopyranoside, 4-[[4-(3-hydroxypropoxy)-2-methoxyphenyl]methyl]-1-(1-methylethyl)-5-[4-(1-methylethyl)phenyl]-1H-pyrazol-3-yl (CA INDEX NAME)


Absolute stereochemistry.

McIntosh

Absolute stereochemistry.



Absolute stereochemistry.




McIntosh

10/529,895

RN 678994-83-7 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(4-methoxyphenyl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl, 2,3,4,6-tetraacetate (CA INDEX NAME)


Absolute stereochemistry.



RN 678994-96-2 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl, 2,3,4,6-tetraacetate (CA INDEX NAME)


Absolute stereochemistry.



RN 678995-00-1 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(3,5-dimethoxyphenyl)methyl]-5-(4-methoxyphenyl)-1-(1-methylethyl)-1H-pyrazol-3-yl, 2,3,4,6-tetraacetate (CA INDEX NAME)

Absolute stereochemistry.



RN 678995-10-3 CAPLUS


CN  $\beta$ -D-Glucopyranoside, 5-[4-(dimethylamino)phenyl]-4-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl,

McIntosh

10/529,895

2,3,4,6-tetraacetate (CA INDEX NAME)


Absolute stereochemistry.



RN 678995-14-7 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[(4-hydroxy-2-methoxyphenyl)methyl]-5-(4-methoxyphenyl)-1-(1-methylethyl)-1H-pyrazol-3-yl, 2,3,4,6-tetrakis(2,2-dimethylpropanoate) (CA INDEX NAME)


Absolute stereochemistry.



RN 678995-15-8 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 4-[[2-methoxy-4-(1-methylethoxy)phenyl]methyl]-5-(4-methoxyphenyl)-1-(1-methylethyl)-1H-pyrazol-3-yl, 2,3,4,6-tetrakis(2,2-dimethylpropanoate) (CA INDEX NAME)

Absolute stereochemistry.




McIntosh

10/529,895

RN 678995-16-9 CAPLUS

CN Acetamide, 2-[3-methoxy-4-[[5-(4-methoxyphenyl)-1-(1-methylethyl)-3-  
[(2,3,4,6-tetra-O-acetyl- $\beta$ -D-glucopyranosyl)oxy]-1H-pyrazol-4-  
yl]methyl]phenoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 678995-17-0 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(4-methoxyphenyl)-4-[[2-methoxy-4-[2-(  
phenylmethoxy)ethoxy]phenyl]methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl,  
2,3,4,6-tetrakis(2,2-dimethylpropanoate) (CA INDEX NAME)

Absolute stereochemistry.




RN 678995-18-1 CAPLUS

CN  $\beta$ -D-Glucopyranoside, 5-(4-methoxyphenyl)-4-[[2-methoxy-4-[2-(  
phenylmethoxy)ethoxy]phenyl]methyl]-1-(1-methylethyl)-1H-pyrazol-3-yl  
(CA INDEX NAME)

Absolute stereochemistry.


McIntosh



RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2003:491188 CAPLUS  
DN 139:69057  
TI Preparation of carbamates as hormone-sensitive lipase inhibitors for the  
treatment of diabetes and related disorders  
IN Ebdrup, Soren; Hansen, Holger Claus; Vedso, Per; Cornelis De Jong,  
Johannes; Jacobsen, Poul  
PA Novo Nordisk A/S, Den.  
SO PCT Int. Appl., 390 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051842	A2	20030626	WO 2002-DK853	20021213
WO 2003051842	A3	20040603		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002351732	A1	20030630	AU 2002-351732	20021213
US 20030166690	A1	20030904	US 2002-319212	20021213
US 7067517	B2	20060627		
US 20030166644	A1	20030904	US 2002-319885	20021213
US 7279470	B2	20071009		
EP 1458375	A2	20040922	EP 2002-787449	20021213
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
CN 1602191	A	20050330	CN 2002-828075	20021213
JP 2005518377	T	20050623	JP 2003-552729	20021213
ZA 2004004324	A	20050721	ZA 2004-4324	20040602
PRAI DK 2001-1879	A	20011214		
DK 2002-645	A	20020430		
DK 2002-1000	A	20020629		
DK 2002-1562	A	20021011		
US 2002-346909P	P	20020103		
US 2002-384253P	P	20020510		
US 2002-393068P	P	20020628		
US 2002-418481P	P	20021015		
WO 2002-DK853	W	20021213		
OS MARPAT 139:69057				
GI				




AB Title compds. I [wherein R1 = H or (un)substituted (cyclo)alkyl or alkenyl; R2 = (un)substituted (cyclo)alkyl, alkenyl, (hetero)aryl, or heterocyclyl; or NR1R2 = heterocyclyl; X = O or S; L = a hydrolyzable group; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, racemates, or polymorphs thereof] were prepared as inhibitors of hormone-sensitive lipase (HSL). For example, esterification of morpholine-4-carbonyl chloride with 4-(3,5-dichloropyridin-4-yloxy)phenol in the presence of DABCO in THF gave II, which showed 88% inhibition of HSL at a concentration of 10  $\mu$ M. Thus, I and pharmaceutical compns. thereof are useful for the treatment and/or prevention of medical disorders where a decreased activity of hormone-sensitive lipase is desirable, such as diabetes (no data).

IT 548767-36-8P, N-Methyl-N-phenylcarbamic acid 4-benzyl-5-(4-methoxyphenyl)-3-(4-methylphenyl)pyrazol-1-yl ester  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (lipase inhibitor; preparation of carbamates as HSL inhibitors for treatment of diabetes and related disorders)

RN 548767-36-8 CAPLUS


CN 1H-Pyrazole, 5-(4-methoxyphenyl)-3-(4-methylphenyl)-1-[[ (methylphenylamino)carbonyl]oxy]-4-(phenylmethyl)- (9CI) (CA INDEX NAME)



IT 548767-37-9, 1-Hydroxy-4-benzyl-5-(4-methoxyphenyl)-3-(4-methylphenyl)pyrazole  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of carbamates as HSL inhibitors for treatment of diabetes and related disorders)


RN 548767-37-9 CAPLUS

CN 1H-Pyrazole, 1-hydroxy-5-(4-methoxyphenyl)-3-(4-methylphenyl)-4-(phenylmethyl)- (CA INDEX NAME)



L4 ANSWER 14 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2003:491187 CAPLUS  
 DN 139:69056  
 TI Preparation of carbamates as hormone-sensitive lipase inhibitors for the treatment of diabetes and related disorders  
 IN Ebdrup, Soren; Cornelis De Jong, Johannes; Jacobsen, Poul; Hansen, Holger Claus; Vedso, Per  
 PA Novo Nordisk A/S, Den.  
 SO PCT Int. Appl., 519 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003051841	A2	20030626	WO 2002-DK852	20021213
	WO 2003051841	A3	20040624		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2468413	A1	20030626	CA 2002-2468413	20021213
	AU 2002351731	A1	20030630	AU 2002-351731	20021213
	US 20030166690	A1	20030904	US 2002-319212	20021213
	US 7067517	B2	20060627		
	US 20030166644	A1	20030904	US 2002-319885	20021213
	US 7279470	B2	20071009		
	EP 1458374	A2	20040922	EP 2002-787448	20021213
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
	CN 1602191	A	20050330	CN 2002-828075	20021213
	BR 2002014967	A	20050510	BR 2002-14967	20021213
	JP 2005518376	T	20050623	JP 2003-552728	20021213
	HU 2005001011	A2	20060130	HU 2005-1011	20021213
	RU 2317981	C2	20080227	RU 2004-121461	20021213
	ZA 2004004324	A	20050721	ZA 2004-4324	20040602
	IN 2004CN01295	A	20070727	IN 2004-CN1295	20040611
	MX 2004PA05790	A	20040913	MX 2004-PA5790	20040614
	NO 2004002962	A	20040908	NO 2004-2962	20040713
PRAI	DK 2001-1879	A	20011214		
	DK 2002-645	A	20020430		
	DK 2002-1000	A	20020629		
	DK 2002-1562	A	20021011		
	US 2002-346909P	P	20020103		
	US 2002-384253P	P	20020510		
	US 2002-393068P	P	20020628		
	US 2002-418481P	P	20021015		
	WO 2002-DK852	W	20021213		
OS	MARPAT 139:69056				
GI					



AB Title compds. I [wherein R1 = H or (un)substituted (cyclo)alkyl or alkenyl; R2 = (un)substituted (cyclo)alkyl, alkenyl, (hetero)aryl, or heterocyclyl; or NR1R2 = heterocyclyl; X = O or S; L = a hydrolyzable group; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, racemates, or polymorphs thereof] were prepared as inhibitors of hormone-sensitive lipase (HSL). For example, esterification of morpholine-4-carbonyl chloride with 4-(3,5-dichloropyridin-4-yloxy)phenol in the presence of DABCO in THF gave II, which showed 88% inhibition of HSL at a concentration of 10  $\mu$ M. Thus, I and pharmaceutical compns. thereof are useful for the treatment and/or prevention of medical disorders where a decreased activity of hormone-sensitive lipase is desirable, such as diabetes (no data).


IT 548767-36-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(lipase inhibitor; preparation of carbamates as HSL inhibitors for treatment of diabetes and related disorders)

RN 548767-36-8 CAPLUS

CN 1H-Pyrazole, 5-(4-methoxyphenyl)-3-(4-methylphenyl)-1-[[[(methylphenylamino)carbonyl]oxy]-4-(phenylmethyl)-(9CI) (CA INDEX NAME)




IT 548767-37-9

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of carbamates as HSL inhibitors for treatment of diabetes and related disorders)

RN 548767-37-9 CAPLUS


CN 1H-Pyrazole, 1-hydroxy-5-(4-methoxyphenyl)-3-(4-methylphenyl)-4-(phenylmethyl)- (CA INDEX NAME)




10/529,895

L4 ANSWER 15 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2003:279804 CAPLUS  
DN 138:294714  
TI Organic electroluminescent device using pyrazole or pyrazoline  
IN Suzuki, Koichi; Ueno, Kazunori; Senoo, Akihiro  
PA Canon Inc., Japan  
SO Jpn. Kokai Tokkyo Koho, 25 pp.  
CODEN: JKXXAF  
DT Patent  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2003109765	A	20030411	JP 2001-300548	20010928
PRAI	JP 2001-300548		20010928		
OS	MARPAT 138:294714				
GI					



AB The invention refers to an organic electroluminescent device comprising pyrazole or pyrazoline I [R1 = H, alkyl, (un)substituted aralkyl, aryl, heterocyclic, condensed polycyclic aromatic or heterocyclic; Ar1-3 = (un)substituted aryl, heterocyclic, condensed polycyclic aromatic or heterocyclic; at least two of R1, Ar1-3 are (un)substituted condensed polycyclic aromatic or heterocyclic groups].  
IT 504414-91-9  
RL: DEV (Device component use); USES (Uses)  
(organic electroluminescent device using pyrazole or pyrazoline)  
RN 504414-91-9 CAPLUS  
CN 1H-Pyrazole, 1-(1-naphthalenyl)-3,5-di-3-perylenyl-4-(phenylmethyl)- (CA INDEX NAME)




L4 ANSWER 16 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2002:855864 CAPLUS  
DN 139:214344  
TI Product class 1: pyrazoles  
AU Stanovnik, B.; Svete, J.  
CS Faculty of Chemistry and Chemical Technology, Division of Organic Chemistry, Ljubljana, 61000, Slovenia  
SO Science of Synthesis (2002), 12, 15-225  
CODEN: SSCYJ9  
PB Georg Thieme Verlag


McIntosh

10/529,895

DT Journal; General Review  
LA English  
AB A review. Methods for preparing pyrazoles are reviewed including cyclization, ring transformation, aromatization and substituent modifications.  
IT 118472-50-7P 371772-77-9P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of pyrazoles via cyclization, ring transformation, aromatization and substituent modifications)  
RN 118472-50-7 CAPLUS  
CN 1H-Pyrazole, 1,3,5-triphenyl-4-(phenylmethyl)- (CA INDEX NAME)



RN 371772-77-9 CAPLUS  
CN 1H-Pyrazole, 5-(4-methylphenyl)-1,3-diphenyl-4-(phenylmethyl)- (CA INDEX NAME)




RE.CNT 909 THERE ARE 909 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2002:171866 CAPLUS  
DN 136:232313  
TI Preparation of pyrimidine derivatives as G protein-coupled receptor kinase (GRK) inhibitors  
IN Fukumoto, Shoji; Watanabe, Toshifumi; Ikeda, Shota  
PA Takeda Chemical Industries, Ltd., Japan  
SO PCT Int. Appl., 322 pp.  
CODEN: PIXXD2  
DT Patent  
LA Japanese  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002018350	A1	20020307	WO 2001-JP7397	20010829
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2001082520	A5	20020313	AU 2001-82520	20010829
	JP 2002145778	A	20020522	JP 2001-259683	20010829
PRAI	JP 2000-264499	A	20000829		
	WO 2001-JP7397	W	20010829		
OS	MARPAT 136:232313				
GI					

McIntosh



AB Disclosed are novel GRK inhibitors which contains compds. represented by the formula (I), a salt thereof, or a prodrug comprising either of these (wherein ring A represents optionally further substituted nitrogen-containing heterocycle; R1 and R2 each represents optionally substituted amino; and X represents a spacer comprising a linear part constituted of one to four atoms, provided that R1 may be bonded to R2 or/and X to form a ring). They are useful as preventives/remedies for cardiac failure. Thus, 5.48 g K<sub>2</sub>CO<sub>3</sub> and 7.52 g 2-aminophenyl 2-nitrophenyl sulfide were added to a suspension of 5.61 g 4-amino-5-bromomethyl-2-methylpyrimidine hydrobromide in 40 mL acetone at room temperature and stirred at 65° for 64 h to give 2.36 g N-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-N-[2-[(2-nitrophenyl)thio]phenyl]amine (II). All 10 compds. tested including II at 30 μM inhibited 30% human GRK2 expressed by human GRK2 gene in COS-7 cells. A capsule and a tablet formulation containing II were also prepared

IT 403515-13-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine derivs. as G protein-coupled receptor kinase (GRK) inhibitors for prevention and/or treatment for cardiac failure)

RN 403515-13-9 CAPLUS

CN Benzamide, N-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-4-[(3,5-diphenyl-1H-pyrazol-4-yl)methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A


Me

RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 2001:658144 CAPLUS  
DN 135:344418

McIntosh

TI Regioselective Synthesis of Polysubstituted Pyrazoles and Isoxazoles  
 AU Katritzky, Alan R.; Wang, Mingyi; Zhang, Suoming; Voronkov, Michael V.;  
 Steel, Peter J.  
 CS Department of Chemistry Center for Heterocyclic Compounds, University of  
 Florida, Gainesville, FL, 32611-7200, USA  
 SO Journal of Organic Chemistry (2001), 66(20), 6787-6791  
 CODEN: JOCEAH; ISSN: 0022-3263  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 135:344418  
 AB A regioselective synthesis has been developed for the preparation of unsym.  
 1,3,5-triaryl-4-alkylpyrazolines and -pyrazoles by treatment of  
 $\alpha$ -benzotriazolyl- $\alpha,\beta$ -unsatd. ketones with monosubstituted  
 hydrazines followed by alkylation at the 4-position of the pyrazoline  
 ring. Reaction of  $\alpha$ -benzotriazolyl- $\alpha,\beta$ -unsatd. ketones  
 with hydroxylamine gives 3,5-disubstituted isoxazoles regioselectively.  
 IT 371772-77-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (regioselective synthesis of polysubstituted pyrazoles and isoxazoles)  
 RN 371772-77-9 CAPLUS  
 CN 1H-Pyrazole, 5-(4-methylphenyl)-1,3-diphenyl-4-(phenylmethyl)- (CA INDEX  
 NAME)




RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 2000:117030 CAPLUS  
 DN 132:166234  
 TI Preparation of estrogen receptor modulating pyrazoles  
 IN Huebner, Verena D.; Lin, Xiaodong; James, Ian; Chen, Liya; Desai, Manoj;  
 Krywult, Beata; Singh, Rajinder; Wang, Liang  
 PA Chiron Corp., USA  
 SO PCT Int. Appl., 124 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000007996	A2	19990806	WO 1999-US17799	19990806
WO 2000007996	A3	20000831		
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9954677	A	20000228	AU 1999-54677	19990806
EP 1102753	A2	20010530	EP 1999-940917	19990806
EP 1102753	B1	20070228		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY			
US 6291505	B1	20010918	US 1999-369747	19990806
JP 2002522422	T	20020723	JP 2000-563630	19990806
AT 355279	T	20060315	AT 1999-940917	19990806
ES 2281186	T3	20070916	ES 1999-940917	19990806
US 20020111374	A1	20020815	US 2001-954039	20010918
US 20040034081	A9	20040219		


10/529,895

	US 6727273	B2	20040427		
	US 20040077701	A1	20040422	US 2003-461914	20030612
	US 39708	E1	20070626	US 2004-757347	20040113
PRAI	US 1998-95772P	P	19980807		
	US 1998-95773P	P	19980807		
	US 1999-369747	A3	19990806		
	WO 1999-US17799	W	19990806		
	US 2001-954039	A1	20010918		
OS	MARPAT 132:166234				
GI					



AB The title compds. [I and II; R1, R3 = alkyl, aryl, heteroaryl, etc.; R2 = H, halo, CN, etc.; R4 = H, CO<sub>2</sub>H, CHO, etc.] which have been found to have unexpected and surprising activity in modulating estrogen receptor activity, and therefore are useful for treating or preventing estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease, were prepared E.g., a multi-step synthesis of II [R1 = Ph<sub>2</sub>CH; R2 = Et; R3 = 4-HOC<sub>6</sub>H<sub>4</sub>; R4 = Me], starting with 4'-methoxybutyrylphenone and 2,2-diphenylacetyl chloride, was given (no data for intermediates). Biol. data for compds. I and II were presented.


IT 258845-58-8P 258845-59-9P 258845-60-2P  
258845-61-3P 258845-99-7P 258846-01-4P  
258846-03-6P 258846-05-8P 258848-04-3P  
258848-17-8P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of estrogen receptor modulating pyrazoles)  
RN 258845-58-8 CAPLUS  
CN Phenol, 4,4'-[1-(4-bromophenyl)-4-(phenylmethyl)-1H-pyrazole-3,5-diyl]bis-  
(9CI) (CA INDEX NAME)



RN 258845-59-9 CAPLUS  
CN Phenol, 4,4'-[1-(4-chloro-2-methylphenyl)-4-(phenylmethyl)-1H-pyrazole-3,5-diyl]bis- (9CI) (CA INDEX NAME)


McIntosh

10/529,895




RN 258845-60-2 CAPLUS

CN Phenol, 4,4'-[1-(3-chlorophenyl)-4-(phenylmethyl)-1H-pyrazole-3,5-diyl]bis-  
(9CI) (CA INDEX NAME)



RN 258845-61-3 CAPLUS

CN Phenol, 4,4'-[1-(4-chlorophenyl)-4-(phenylmethyl)-1H-pyrazole-3,5-diyl]bis-  
(9CI) (CA INDEX NAME)




RN 258845-99-7 CAPLUS


CN Phenol, 3-[[3,5-bis(4-hydroxyphenyl)-4-(phenylmethyl)-1H-pyrazol-1-yl]methyl]-  
(CA INDEX NAME)

McIntosh


10/529,895



RN 258846-01-4 CAPLUS  
CN Phenol, 4,4'-[1-[4-(methylsulfonyl)phenyl]-4-(phenylmethyl)-1H-pyrazole-3,5-diyl]bis- (9CI) (CA INDEX NAME)




RN 258846-03-6 CAPLUS  
CN Phenol, 4,4'-[1-(pentafluorophenyl)-4-(phenylmethyl)-1H-pyrazole-3,5-diyl]bis- (9CI) (CA INDEX NAME)



RN 258846-05-8 CAPLUS  
CN Phenol, 4,4'-[4-(phenylmethyl)-1-[4-(trifluoromethoxy)phenyl]-1H-pyrazole-3,5-diyl]bis- (9CI) (CA INDEX NAME)


McIntosh

10/529,895




RN 258848-04-3 CAPLUS

CN Phenol, 4,4'-[1-cyclobutyl-4-(phenylmethyl)-1H-pyrazole-3,5-diyl]bis-  
(9CI) (CA INDEX NAME)



RN 258848-17-8 CAPLUS

CN Phenol, 4-[1-(2-fluorophenyl)-5-(4-methylphenyl)-4-(phenylmethyl)-1H-pyrazol-3-yl]-  
(CA INDEX NAME)



L4 ANSWER 20 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1998:780010 CAPLUS

DN 130:125020

TI Synthesis of potassium tris(substituted pyrazolyl) hydroboride

AU Guo, Shengi; Li, Xianjun; Yin, Yuanqi

CS Department of Chemistry, Sichuan University, Chengdu, 610064, Peop. Rep. China

SO Huaxue Yanjiu Yu Yingyong (1998), 10(4), 406-409

CODEN: HYYIFM; ISSN: 1004-1656


PB Huaxue Yanjiu Yu Yingyong Bianjibu

DT Journal

McIntosh

10/529,895

LA Chinese  
GI




AB Potassium pyrazole hydroboride derivs. (I; R1 = CH3, Ph; R3= thiophenyl, Ph) were synthesized and fully characterized. The position-isomer and <sup>1</sup>H NMR spectra of these compds. were also discussed.

IT 219863-66-8P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(synthesis of potassium tris(substituted pyrazolyl) hydroboride)

RN 219863-66-8 CAPLUS

CN 1H-Pyrazole, 3-phenyl-4-(phenylmethyl)-5-(2-thienyl)- (CA INDEX NAME)



L4 ANSWER 21 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1997:44662 CAPLUS

DN 126:59751

OREF 126:11733a,11736a

TI Preparation of di- and tricarboxybenzamides and analogs as squalene synthetase and protein farnesyltransferase inhibitors

IN Baker, William R.; Rosenberg, Saul H.; Fung, K. L. Anthony; Rockway, Todd W.; Fakhoury, Stephen A.; Garvey, David S.; Donner, B. Gregory; O'Connor, Stephen J.; Prasad, Rajnandan N.; Shen, Wang; Stout, David M.; Sullivan, Gerard M.

PA Abbott Laboratories, USA

SO PCT Int. Appl., 241 pp.  
CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9634851	A1	19961107	WO 1996-US6193	19960502
	W: AU, CA, JP, KR, MX				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 5783593	A	19980721	US 1996-633262	19960429
	AU 9656731	A	19961121	AU 1996-56731	19960502
PRAI	US 1995-429095	A	19950503		
	US 1996-633262	A	19960429		
	US 1993-147708	B2	19931104		
	US 1994-289711	B2	19940909		
	US 1994-322783	B2	19941018		
	WO 1996-US6193	W	19960502		
OS	MARPAT 126:59751				
GI					

McIntosh




AB Title compds. [e.g., I; A1 = ZCONR1R2; A2, A4, and A5 or A2 and A4 or A3 and A4 = (protected) CO<sub>2</sub>H and the other An = H; R1 = (chloro)benzyl, (CH<sub>2</sub>)<sub>2</sub>-4Ph, CH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>(OPh)-4; R2 = (CH<sub>2</sub>)<sub>1</sub>-2C<sub>6</sub>H<sub>4</sub>(OPh)-4; Z = bond, NR, O; R = H, (cyclo)alkyl, aralkyl, cycloalkylalkyl] were prepared. Thus, 4-(PhO)C<sub>6</sub>H<sub>4</sub>CHO was reductively aminated by H<sub>2</sub>CH<sub>2</sub>Ph and the product amidated by 1,2,4,5-benzenetetracarboxylic dianhydride to give title compound II. Data for in vitro inhibition of protein farnesyltransferase by selected I were given.

IT 185049-89-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of di- and tricarboxybenzamides and analogs as squalene synthetase and protein farnesyltransferase inhibitors)

RN 185049-89-2 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 4-[5-(4-phenoxyphenyl)-4-(phenylmethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




IT 185051-22-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of di- and tricarboxybenzamides and analogs as squalene synthetase and protein farnesyltransferase inhibitors)


RN 185051-22-3 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 4-[5-(4-phenoxyphenyl)-4-(phenylmethyl)-1H-pyrazol-3-yl]-, dimethyl ester (9CI) (CA INDEX NAME)




10/529,895

L4 ANSWER 22 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 1992:59269 CAPLUS  
DN 116:59269  
OREF 116:10257a,10260a  
TI Structure-activity relationships associated with 3,4,5-triphenyl-1H-pyrazole-1-nonanoic acid, a nonprostanoid prostacyclin mimetic  
AU Meanwell, Nicholas A.; Rosenfeld, Michael J.; Wright, J. J. Kim; Brassard, Catherine L.; Buchanan, John O.; Federici, Marianne E.; Fleming, J. Stuart; Seiler, Steven M.  
CS Bristol-Myers Squibb Pharm. Res. Inst., Wallingford, CT, 06492, USA  
SO Journal of Medicinal Chemistry (1992), 35(2), 389-97  
CODEN: JMCMAR; ISSN: 0022-2623  
DT Journal  
LA English  
OS CASREACT 116:59269  
GI




AB A series of phenylated pyrazolealkanoic acids, e.g., I (R = (CH<sub>2</sub>)<sub>n</sub>CO<sub>2</sub>H, n = 5-10, R<sub>1</sub>, R<sub>3</sub> = H, Ph, R<sub>2</sub> = Ph, PhCH<sub>2</sub>, Et; R = (CH<sub>2</sub>)<sub>6</sub>XCH<sub>2</sub>CO<sub>2</sub>H, X = O, S, S(O), SO<sub>2</sub>, R<sub>1</sub> = R<sub>2</sub> = R<sub>3</sub> = Ph) and related derivs. were prepared as inhibitors of ADP-induced human platelet aggregation.  
3,4,5-Triphenyl-1H-pyrazole-1-nonanoic acid (II), with an IC<sub>50</sub> of 0.4 μM, was the most potent inhibitor. Biochem. studies determined that II increased intraplatelet cAMP accumulation and stimulated platelet membrane-bound adenylate cyclase in a concentration-dependent fashion. Displacement of [<sup>3</sup>H]iloprost by II from platelet membranes indicated that the platelet prostacyclin (PGI<sub>2</sub>) receptor is the locus of biol. action. Structure-activity studies demonstrated that the min. structural requirements for binding to the platelet PGI<sub>2</sub> receptor and inhibition of ADP-induced platelet aggregation within this series are a vicinally diphenylated pyrazole substituted with an ω-alkanoic acid side chain 8 or 9 atoms long. Potency depended upon both side-chain length and its topol. relationship with the two Ph rings.  
IT 137743-31-8  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(blood platelet aggregation inhibiting activity of)  
RN 137743-31-8 CAPLUS  
CN 1H-Pyrazole-1-nonanoic acid, 3,5-diphenyl-4-(phenylmethyl)- (CA INDEX NAME)



L4 ANSWER 23 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN  
AN 1989:94258 CAPLUS  
DN 110:94258  
OREF 110:15563a,15566a  
TI Cycloaddition of some diarylnitrilimines to various 2-arylidene-1-indanones. Regio- and diastereochemistry of spiropyrazoline synthesis  
AU Kerbal, Abdelali; Tshiamala, Kabula; Vebrel, Joel; Laude, Bernard  
CS Fac. Sci., Univ. Franche-Comte, Besancon, 25030, Fr.  
SO Bulletin des Societes Chimiques Belges (1988), 97(2), 149-61  
CODEN: BSCBAG; ISSN: 0037-9646  
DT Journal  
LA French  
OS CASREACT 110:94258  
GI

McIntosh




AB 1,3-Dipolar cycloaddn. of the title indanones I (R1 = H, Me; R2 = H, Me, Ph; R = H, Me, OMe) with 4-R4C6H4C.tplbond.N+N-Ph (R4 = H, Me, OMe, Cl, NO2) gave spiropyrazolines II. The cycloaddn. was regio- and stereospecific. Thus, the dipole approaches from the less hindered face of the dipolarophile.

IT 118472-50-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 118472-50-7 CAPLUS

CN 1H-Pyrazole, 1,3,5-triphenyl-4-(phenylmethyl)- (CA INDEX NAME)



L4 ANSWER 24 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1982:16078 CAPLUS

DN 96:16078

OREF 96:2667a,2670a

TI Composition containing a pyrazolium salt for retarding the growth of sunflower

IN Shafer, Neal E.; Bhalla, Prithvi Raj

PA American Cyanamid Co. , USA

SO Fr. Demande, 28 pp.

CODEN: FRXXBL


DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	FR 2475853	A1	19810821	FR 1981-3167	19810218
	CA 1151890	A1	19830816	CA 1981-369468	19810128
	BR 8100964	A	19810825	BR 1981-964	19810218
	AU 8167409	A	19810827	AU 1981-67409	19810218
	ZA 8101086	A	19820331	ZA 1981-1086	19810218
	ES 499545	A1	19820901	ES 1981-499545	19810218
	HU 27555	A2	19831028	HU 1981-390	19810218
PRAI	US 1980-122642	A	19800219		

GI



10/529,895

AB The pyrazolium salts I or II (R1 and R2 C1-3 alkyl or Ph; R4 = H, OH, C1-18 alkyl, haloalkyl, alkoxy, PhCH2, substituted Ph, etc.; R3 and R5 = C1-12 alkyl, alkoxy, cycloalkyl, halo, NH2, PhNH, EtO, naphthyloxy, heterocyclic radical, etc.; R6 = H or Me; X = acetate, sulfate, etc.; m = 1, 2, or 3) are growth inhibitors for sunflower. Thus, preplant 1,2-dimethyl-3,5-diphenylpyrazolium Me sulfate [43222-48-6] (0.25 kg/ha) decreased the height of sunflower by 69.6%.

IT 80068-90-2

RL: BIOL (Biological study)

(plant growth inhibitor, for sunflower)


RN 80068-90-2 CAPLUS

CN 1H-Pyrazolium, 1,2-dimethyl-3,5-diphenyl-4-(phenylmethyl)-, sulfate (2:1)  
(CA INDEX NAME)

CM 1

CRN 59876-16-3


CMF C24 H23 N2



CM 2

CRN 14808-79-8

CMF O4 S



L4 ANSWER 25 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1977:89813 CAPLUS

DN 86:89813

OREF 86:14185a,14188a

TI Diphenylpyrazolium salts

IN Cross, Barrington; Walworth, Bryant L.

PA American Cyanamid Co., USA

SO Ger. Offen., 39 pp.

CODEN: GWXXBX

DT Patent


LA German

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	DE 2618421	A1	19761118	DE 1976-2618421	19760427
	US 3958001	A	19760518	US 1975-574067	19750502
	US 4017298	A	19770412	US 1975-574068	19750502
	ZA 7602247	A	19770427	ZA 1976-2247	19760414
PRAI	US 1975-574067	A	19750502		
	US 1975-574068	A	19750502		
GI					

McIntosh

10/529,895



AB The title compds. I (R = Me, Et, Pr, Me<sub>2</sub>CH, HO<sub>2</sub>CCH<sub>2</sub>, CH<sub>2</sub>:CHCH<sub>2</sub>, HC.tplbond.CCH<sub>2</sub>, PhCH<sub>2</sub>; X = I, ClO<sub>4</sub>, MeSO<sub>4</sub>, HSO<sub>4</sub>), useful as fungicides and herbicides, are prepared by quaternization of the appropriate pyrazoles which are obtained by cyclocondensation of PhCOCHRCOPh with MeNHNH<sub>2</sub>. Thus, reaction of 1,4-dimethyl-3,5-diphenylpyrazole with Me<sub>2</sub>SO<sub>4</sub> in PhMe at 80°, followed by 3 hr stirring at 100°, gives 72% I (R = Me, X = MeSO<sub>4</sub>). 1,2,4-Trimethyl-3,5-dicyclohexylpyrazolium methyl sulfate is prepared similarly.

IT 59876-17-4P 59876-18-5P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and herbicidal activity of)


RN 59876-17-4 CAPLUS

CN 1H-Pyrazolium, 1,2-dimethyl-3,5-diphenyl-4-(phenylmethyl)-, sulfate (1:1)  
 (CA INDEX NAME)

CM 1

CRN 59876-16-3


CMF C24 H23 N2



CM 2

CRN 14996-02-2

CMF H O4 S




RN 59876-18-5 CAPLUS

CN 1H-Pyrazolium, 1,2-dimethyl-3,5-diphenyl-4-(phenylmethyl)-, perchlorate  
 (9CI) (CA INDEX NAME)

CM 1

CRN 59876-16-3

CMF C24 H23 N2




McIntosh

10/529,895

CM 2

CRN 14797-73-0

CMF Cl O4




IT 59876-05-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and quaternization of)

RN 59876-05-0 CAPLUS

CN 1H-Pyrazole, 1-methyl-3,5-diphenyl-4-(phenylmethyl)- (CA INDEX NAME)



L4 ANSWER 26 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1976:560086 CAPLUS

DN 85:160086

OREF 85:25629a,25632a

TI 4-Alkyl-1,2-dimethyl-3,5-diphenylpyrazolium salts and derivatives as fungicidal agents

IN Cross, Barrington; Walworth, Bryant L.

PA American Cyanamid Co., USA

SO U.S., 7 pp.

CODEN: USXXAM


DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	US 3963741	A	19760615	US 1975-619092	19751002
	US 3958001	A	19760518	US 1975-574067	19750502
PRAI	US 1975-574067	A3	19750502		

GI



AB Pyrazolium salts I (R = Me, Pr, CHMe2, pentyl, CH2Ph, X = ClO4; R = Me, Et, X = MeSO4; R = CH2C.tplbond.CH, CH2Ph, allyl, X = HSO4; R = CH2CO2Et, X = I) were prepared by alkylating NaCHBz2, cyclizing RCHBz2 with MeNHNH2, treating the pyrazoles with Me2SO4 and optionally changing the anion. I controlled powder mildews on cucumbers, wheat, and barley at ≤500 ppm.

IT 59876-17-4P 59876-18-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and fungicidal activity of)

McIntosh

10/529,895


RN 59876-17-4 CAPLUS

CN 1H-Pyrazolium, 1,2-dimethyl-3,5-diphenyl-4-(phenylmethyl)-, sulfate (1:1)  
(CA INDEX NAME)

CM 1

CRN 59876-16-3


CMF C24 H23 N2



CM 2

CRN 14996-02-2

CMF H O4 S




RN 59876-18-5 CAPLUS

CN 1H-Pyrazolium, 1,2-dimethyl-3,5-diphenyl-4-(phenylmethyl)-, perchlorate  
(9CI) (CA INDEX NAME)

CM 1

CRN 59876-16-3


CMF C24 H23 N2



CM 2

CRN 14797-73-0

CMF Cl O4



IT 59876-05-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and quaternization of)

RN 59876-05-0 CAPLUS

McIntosh

10/529,895

CN 1H-Pyrazole, 1-methyl-3,5-diphenyl-4-(phenylmethyl)- (CA INDEX NAME)



L4 ANSWER 27 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1976:463065 CAPLUS

DN 85:63065

OREF 85:10157a,10160a

TI 4-Alkyl-1,2-dimethyl-3,5-diphenylpyrazolium salts and derivatives as fungicidal agents

IN Cross, Barrington; Walworth, Bryant L.

PA American Cyanamid Co., USA

SO U.S., 7 pp.


CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3958001	A	19760518	US 1975-574067	19750502
	US 3963741	A	19760615	US 1975-619092	19751002
	IL 49410	A	19800630	IL 1976-49410	19760413
	AU 7612987	A	19771020	AU 1976-12987	19760414
	AU 503523	B2	19790906		
	CA 1078850	A1	19800603	CA 1976-250620	19760421
	GB 1543338	A	19790404	GB 1976-16439	19760422
	FI 7601159	A	19761103	FI 1976-1159	19760427
	DE 2618421	A1	19761118	DE 1976-2618421	19760427
	BE 841231	A1	19761028	BE 1976-166527	19760428
	NL 7604597	A	19761104	NL 1976-4597	19760429
	FR 2309539	A1	19761126	FR 1976-12809	19760429
	CS 191170	B2	19790629	CS 1976-2833	19760429
	DK 7601944	A	19761103	DK 1976-1944	19760430
	SE 7605011	A	19761103	SE 1976-5011	19760430
	DD 127656	A5	19771005	DD 1976-192622	19760430
	SU 683601	A3	19790830	SU 1976-2354750	19760430
	PL 107282	B1	19800229	PL 1976-189201	19760430
	JP 51133265	A	19761118	JP 1976-50052	19760504
PRAI	US 1975-574067	A3	19750502		
GI	US 1975-574068	A	19750502		



AB PhCOCH<sub>2</sub>COPh was alkylated (NaH) to give PhCOCHRCOPh (R = n-C<sub>5</sub>H<sub>11</sub>, Me, Pr, Me<sub>2</sub>CH, CH<sub>2</sub>C.tplbond.CH, Et, CH<sub>2</sub>CO<sub>2</sub>Et, CH<sub>2</sub>CH:CH<sub>2</sub>, PhCH<sub>2</sub>), which were cyclized with MeNHNH<sub>2</sub> to give the pyrazoles I. I were converted into II (X = MeSO<sub>4</sub>, ClO<sub>4</sub>, I). At 50-550 ppm II controlled rice blast, apple scab, and powdery mildew.

IT 59876-17-4P 59876-18-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and fungicidal activity of)

RN 59876-17-4 CAPLUS


CN 1H-Pyrazolium, 1,2-dimethyl-3,5-diphenyl-4-(phenylmethyl)-, sulfate (1:1)  
(CA INDEX NAME)

McIntosh

10/529,895


CM 1

CRN 59876-16-3  
CMF C24 H23 N2



CM 2


CRN 14996-02-2  
CMF H O4 S



RN 59876-18-5 CAPLUS  
CN 1H-Pyrazolium, 1,2-dimethyl-3,5-diphenyl-4-(phenylmethyl)-, perchlorate  
(9CI) (CA INDEX NAME)


CM 1

CRN 59876-16-3  
CMF C24 H23 N2




CM 2

CRN 14797-73-0  
CMF Cl O4




IT 59876-05-0P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and methylation of)  
RN 59876-05-0 CAPLUS  
CN 1H-Pyrazole, 1-methyl-3,5-diphenyl-4-(phenylmethyl)- (CA INDEX NAME)


McIntosh



L4 ANSWER 28 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 1966:456804 CAPLUS  
 DN 65:56804  
 OREF 65:10587a-c  
 TI Derivatives of 4-(1-pyrazolyl)pyrimidine. II. The synthesis of  
 4-(3,5-diphenyl-4-alkylpyrazolyl)-5-phenylpyrimidines  
 AU Tsatsaronis, G. S.; Mikromastoras, E.; Halivopoulos, S.  
 CS Univ. Thessaloniki, Thessaloniki, Greece  
 SO Chim. Chronika (Athens, Greece) (1966), 31(5), 57-9  
 DT Journal  
 LA English  
 AB cf. CA 61, 11992b. The title compds. (I) were prepared by treating  
 4-hydrazino-5-phenylpyrimidine (II) with 1,3-diphenyl-2-alkyl-1,3-  
 propanedione (III). Thus 2 g. II and 2.5 g. III (alkyl = H) were heated  
 20 min. at 140°, the temperature raised to 160-70° and maintained  
 20 min. more. The resinous product was dissolved in hot MeOH and treated  
 with charcoal to yield 57% I (alkyl = H), m. 119-20°. Similarly  
 prepared were the following I (alkyl, m.p., and yield given): Me,  
 106-8°, 49%; Et, 133-4°, 58%; PhCH<sub>2</sub>, 162°, 46%.  
 Using 4-hydrazino-5-(p-nitrophenyl) pyrimidine instead of II, the  
 following 4-[(3,5-diphenyl-4-alkylpyrazol-1-yl)]-5-(p-nitrophenyl)-  
 pyrimidines were prepared (alkyl, m.p., and % yield given): H,  
 214-15°, 71; Me, 192°, 70; Et, 161-2°, 62; PhCH<sub>2</sub>,  
 157°, 49.  
 IT 7052-31-5P, Pyrimidine, 4-(4-benzyl-3,5-diphenylpyrazol-1-yl)-5-(p-  
 nitrophenyl)- 7200-69-3P, Pyrimidine, 4-(4-benzyl-3,5-  
 diphenylpyrazol-1-yl)-5-phenyl-  
 RL: PREP (Preparation)  
 (preparation of)  
 RN 7052-31-5 CAPLUS  
 CN Pyrimidine, 4-(4-benzyl-3,5-diphenylpyrazol-1-yl)-5-(p-nitrophenyl)- (7CI,  
 8CI) (CA INDEX NAME)



RN 7200-69-3 CAPLUS  
 CN Pyrimidine, 4-(4-benzyl-3,5-diphenylpyrazol-1-yl)-5-phenyl- (7CI, 8CI)  
 (CA INDEX NAME)




L4 ANSWER 29 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN  
 AN 1964:411116 CAPLUS  
 DN 61:11116  
 OREF 61:1786a-h,1787a-b  
 TI Synthetic drugs. XII. Constitution and salidiuretic effect of  
 3-sulfamoyl-4-chlorobenzoic acid derivatives and related compounds  
 AU Jucker, E.; Lindenmann, A.; Schenker, E.; Flueckiger, E.; Taeschler, M.  
 CS Sandoz Ltd., Basel, Switz.  
 SO Arzneimittel-Forschung (1963), 13(4), 269-80  
 CODEN: ARZNAD; ISSN: 0004-4172  
 DT Journal  
 LA Unavailable  
 GI For diagram(s), see printed CA Issue.  
 AB cf. CA 59, 6350b; 60, 15830c. A large number of 3-sulfamoyl-4-chlorobenzoic acid derivs. with the basic structures I-XIII [R, R', and R'' (if present), and m.p. of base or salt given] have been prepared, partially by known methods (CA 59, 10031a), partially by new methods, and were tested for their salidiuretic activity. I prepared were: H, H, HCl salt, 224-5°; (RR' =) 3-pyridylmethylene, 190-2°; (RR' =) 4-ClC<sub>6</sub>H<sub>4</sub>CH, 208-11°; (RR' =) PhCH, 153-4°; H, 3-pyridylmethyl, 160-2° (decomposition); H, 4-ClC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>, 149-51° (decomposition); H, PhCH<sub>2</sub>, 117-18° (decomposition). II prepared were: H, H, HCl salt, 217-19° (decomposition); (RR' =) Me<sub>2</sub>C, 217-19° (decomposition); H, 4-ClC<sub>6</sub>H<sub>4</sub>CO, 215-17°; H, Bz, 242-4°; H, PhCH<sub>2</sub>CO, 151-3°. III prepared were: Me, H, EtO, 192-4°; 4-ClC<sub>6</sub>H<sub>4</sub>, H, 4-ClC<sub>6</sub>H<sub>4</sub>, 250-1°; Ph, H, Ph, 251-3°; Ph, Et, Ph, 191-2°; Ph, PhCH<sub>2</sub>, Ph, 211-13°. IV prepared were: Me, H, 230-2°; Me, Et, 188-9°; Ph, H, 218-20°; Ph, o-ClC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>, 115-16°. V prepared were: F, Me, 136-8°; Cl, Me, 154-5°; Br, Me, 155-6°; Cl, Et, 155-6°; Cl, CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H, 166-7°; Cl, Pr, 145-6°; Cl, CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>Me, 112-13°. VI prepared were: CHO, 161-4° (decomposition); PhNH<sub>2</sub>:CH, 236-9° (decomposition); CH<sub>2</sub>OH, 143-5° (decomposition); 4,3-Cl(H<sub>2</sub>NO<sub>2</sub>S)C<sub>6</sub>H<sub>3</sub>CO<sub>2</sub>CH<sub>2</sub>, 226-9° (decomposition); MeCH(OH), 142-4°; EtCH(OH), 131-3° (decomposition); PrCH(OH), 109-110 (decomposition). VII prepared were: Cl, CH<sub>2</sub>tpbond.CCH<sub>2</sub>, 112-13°; Cl, 2-thienylmethyl, 133-4°; Cl, cyclopentyl, 163-4°; Cl, 2-tetrahydrofurfurylmethyl, 130-1° (F analog m. 91-3°); Cl, 2-pyridylmethyl, 170-1°; Cl, 3-pyridylmethyl, 189-90°; Cl, 4-pyridylmethyl, 184-5°; Cl, cyclohexyl, 148-9°; Cl, 2-tetrahydropyranylmethyl, 161-3°; Cl, 4-FC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>, 157-8°; Cl, 4-O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>, 157°; Cl, PhCH<sub>2</sub>, 121-2°; F, PhCH<sub>2</sub>, 150-1°; Cl, cycloheptyl, 135-6°; Cl, PhCH<sub>2</sub>CH<sub>2</sub>, 99-100°; Cl, cyclooctyl, 150-3°; Cl, C<sub>8</sub>H<sub>17</sub>, 85°; Cl, 4-quinolylmethyl, 244-5°; Cl, Cl<sub>6</sub>H<sub>33</sub>, 90-1°. VIII prepared were: 2-furfurylmethylamino, 150-2°; 2-tetrahydrofurfurylmethylamino, 169-72°; N-methyl-N'-tetrahydropyrazinyl, 220-4°; 2-(6-chlorobenzothiazolyl)amino, 333-7° (decomposition); 1-(5-methyl-1,5-diazacyclooctyl), 187-90°; N-[N'-(2-chlorophenyl)tetrahydropyrazinyl], 204-6° (3-Cl analog, 192-4°; 4-Cl analog, 192-3°). IX prepared were: H, H, 214-15° (HCl salt, 303-5°); Me, Me, 193-5°; H, EtCO<sub>2</sub>, 208-9°; H, Me<sub>2</sub>CH, 206-7°; H, Bz, 225-7°. X prepared were: Cl, 2-oxooxazolidin-3-yl, 182-3°; F, 1,4-thiazan-4-yl, 250-2°; Cl, morpholino, 267-8°; Cl, piperidino, 230-2°; Cl, 4-methyl-1-piperazinyl, 195-6°; Cl, 1,2,3,4-tetrahydro-1-quinoliny, 270-2°. XI prepared were: Me, CO<sub>2</sub>H, 228-31°; Me, CONH<sub>2</sub>, 199-201°; Me, CO<sub>2</sub>Et, 148-51°; Me, N-(2,6-dimethyl-1-piperidyl)carbamoyl, 306-8°; Cl, CO<sub>2</sub>H, 225-6°; Cl, MeNHNHCO, 240°; Cl, Me<sub>2</sub>NNHCO, 172°; Cl, piperidinocarbamoyl, 214°; Cl, PhNHNHCO, 188-9°; Cl, N-azacyclooctylcarbamoyl, 190-1°. XII prepared were: NH<sub>2</sub>C(S)NH, 195-7° (decomposition); NH<sub>2</sub>CONHNH, 197-9° (decomposition); NH<sub>2</sub>CONHCO, 231-4°; N-propylsultamyl, 180-2°; γ-butyrolactonyl, 153-5°; 5-(5-methyl-2,4-dioxoimidazolidinyl), 278-9°; N-butylsultamyl, 182-4°; PhNHC(S)NH, 185-7°; 2-oxo-5-enyl-1,3,4-oxadiazolin-3-yl, 278-9°; 2-oxo-3-phenyl-1,3,4-oxadiazolin-5-yl, 244-5°; BzNHNHCO, 237-9° (decomposition); PhNHN:CM<sub>e</sub>, 157-8° (decomposition); PhCH<sub>2</sub>CO<sub>2</sub>CH<sub>2</sub>, 117°. XIII prepared were: F, H<sub>2</sub>NCO, 198-9°; MeS, EtOSO<sub>2</sub>, 132-5° (decomposition); MeS, N-propylsultamyl, 193-5°; MeS, N-butylsultamyl, 155-7°; methylsulfinyl, N-butylsultamyl, 195-7°; MeSO<sub>2</sub>,

N-butylsultamyl, 216-18° (decomposition); Cl, PhNHNHSO<sub>2</sub>, 172-4° (decomposition); MeS, PhNHNHSO<sub>2</sub>, 163-5° (decomposition). Intermediate products prepared were: 4,3-Cl(H<sub>2</sub>N)C<sub>6</sub>H<sub>3</sub>COCH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H, m. 167-9° (decomposition); 4,3-Cl(ClO<sub>2</sub>S)C<sub>6</sub>H<sub>3</sub>COCH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H, m. 164-8° (decomposition); 2,4,5-Cl<sub>2</sub>(H<sub>2</sub>NO<sub>2</sub>S)C<sub>6</sub>H<sub>2</sub>COCl, m. 175-6°; 4,3-Cl(H<sub>2</sub>NO<sub>2</sub>S)C<sub>6</sub>H<sub>3</sub>SO<sub>2</sub>Cl, m. 181-3° (decomposition). The pharmacol. results obtained on rats and dogs are given in tables and in graphs. The results obtained with N-(cis-2,6-dimethyl-1-piperidyl)-3-sulfamoyl-4-chlorobenzoic acid amide (DT-327, Chlosudimeprimylum, Brinaldix) are discussed in detail.

IT 96277-00-8P, Benzenesulfonamide, 5-(4-benzyl-3,5-diphenylpyrazol-1-yl)-2-chloro-  
 RL: PREP (Preparation)  
 (preparation of)

RN 96277-00-8 CAPLUS

CN Benzenesulfonamide, 5-(4-benzyl-3,5-diphenylpyrazol-1-yl)-2-chloro- (7CI)  
 (CA INDEX NAME)



L4 ANSWER 30 OF 30 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1964:45682 CAPLUS

DN 60:45682

OREF 60:8014c-e

TI Chemistry of selenophene. XLVIII. Synthesis of di- and tri- substituted pyrazoles containing the selenophene ring

AU Yur'ev, Yu. K.; Magdesieva, N. N.; Titov, V. V.; Brysova, V. P.

CS M. V. Lomonosov State Univ., Moscow

SO Zhurnal Obshchei Khimii (1963), 33(11), 3517-19  
 CODEN: ZOKHA4; ISSN: 0044-460X

DT Journal

LA Unavailable

GI For diagram(s), see printed CA Issue.


AB cf. CA 60, 490g. Refluxing propionyl(2-selenophenecarbonyl)methane with N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O in MeOH 1 hr. gave 63.5% 3-ethyl-5-(2-selenophene-yl)pyrazole (I), m. 108-9°. Similarly, butyroyl(2-selenophenecarbonyl)-methane gave 80% 3-propyl-5-(2-selenophene-yl)pyrazole, m. 90-1°, while methylacetyl(2-selenophenecarbonyl)methane gave 82% 3,4-dimethyl-5-(2-selenophene-yl)pyrazole, m. 150-1°, and ethylacetyl(2-selenophenecarbonyl)methane gave 54% 3-methyl-4-ethyl-5-(2-selenophene-yl)pyrazole, m. 72-3°. α-Naphthoyl(2-selenophenecarbonyl)methane similarly gave 61.5% 3-α-naphthyl-5-(2-selenophene-yl)pyrazole, m. 72-4°, while p-tolyl(2-selenophenecarbonyl)methane gave 76% 3-p-tolyl-5-(2-selenophene-yl)pyrazole, m. 181-1.5°, anisoyl(2-selenophenecarbonyl)methane gave 66% 3-anisyl-5-(2-selenophene-yl)pyrazole, m. 159.5-61°, and picolinoyl(2-selenophenecarbonyl)methane gave 76% 3-α-pyridyl-5-(2-selenophene-yl)pyrazole, m. 146-7°. Refluxing 1,3-dibenzoyl-1,3-bis(2-selenophenecarbonyl)methane with N<sub>2</sub>H<sub>4</sub>.H<sub>2</sub>O in dioxane 2.5 hrs. gave 30.5% bis[3-phenyl-5-(2-selenophene-yl)pyrazol-4-yl]methane, m. 122-5°.

IT 102346-85-0P, Pyrazole, 4,4'-methylenebis[3(or 5)-phenyl-5(or 3)-selenophene-2-yl-  
 RL: PREP (Preparation)  
 (preparation of)

RN 102346-85-0 CAPLUS

CN Pyrazole, 4,4'-methylenebis[3(or 5)-phenyl-5(or 3)-selenophene-2-yl- (7CI)  
 (CA INDEX NAME)

10/529,895



McIntosh